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Abstr:1ct 
Midazolam (Hypnovelll:) is the only sedating agent used by paramedics at St John 
Ambulance Service W.A. in the management of many conditions including seizure 
activities, antisocial or uncontrollable behaviours. back pain incidents and head injuries. 
Midazolam, with a rapid absorption, fast onset of action and short duration on 
neurological activity, has been accepted as a safe and effective agent in prehospital 
treatment since the late-1990s. Often. if a patient is not complying with treatment or is 
uncontrollable or aggressive, paramedics are required to sedate the individual. This 
study primarily examines the use of midazolam for the sedation of unmanageable 
patients who have sustained a head injury in a prehospital setting. The research 
investigated \vhethcr miduzolam (n=49) increases the symptoms of hypntcnsion and 
hypoxia in patients with head injuries in a prebospital setting. Patients that sust~ined a 
head injury but did not receive midazolam (n=47) were used as controls. Physiological 
parameters including blood pressure, pulse and respiration rates, oxygen saturation, 
along with Coma Scale and Visual Analogue Scale were placed into SPSS analysis 
packuge and Excel t-h.'Sts. further unalysis on sub divided cohorts of gender, age and 
severity of head injury was conducted. Results indicated that although significance 
differences were present, miduzolam did not inlluence hypotension or hypoxia in h~Jad 
injured patients. However the nature of the head injury along with behavioural issues 
was the result of incrcused symptoms of hypotension and hypoxia. 
l. Introduction 
Midazolam (llypnovci'!i:) is the only sedating agent used by paramedics at St John 
Ambulance Service W.A. in the managem~nt of many conditions including seizure 
activities, antisocial or uncontrollable behaviours, back pain incidents and head 
injuries 1. Midazolam is a member of the bi:nzodiazepine family of drugs and is regarded 
as a safe alternative to opiates and barbiturates 1. Its lipophilic properties enable rapid 
absorption into the brain with fast onset or action. Similar to diazcpmn hut with a 
shorter duration on neurological activity, midazolam has been accepted as a safe and 
effective agent in prehospital treatments since the late-1990s. 
Emergency medicine rcqmrcs paramedics to expertly manage critical care patients, 
sedated patients, pain managed patients, as well as respiratory and haemodynamieally 
compromised patients. When paramedics arrive at the scene of a severely injured or 
hacmodynamically compromised individual the policy is to cnsun: the patient is 
ddivercd to hospital in a safe and stable manner. For trauma patients the policy that 
ensures effective transport to hospital, where appropriate treatment can begin, is to 
maintain minimal time ut the scene of an accident and maximum treatment on route 1. 
Often if a patient is not complying with treatment or is uncontrollable or aggressive, 
paramedics arc requin;·d to sedate the individuaL In the prehospital setting the bst resort 
is to administer a sedating agent to a patient who is cerebrally hypoxic. has sustuined a 
head injury or is agitated. llmvcver, it is considcrcd appropriate to sedate to manage. 
regardless of a patients· physiological status. In other words, midazolam can be 
administered to a patient \vho is not compliant or is uncontrollah\c, in order for them to 
be transported to hospital for appropri<.ttc treatment J. 
There is a growing amount of literature suggesting that midazolam is a safC and 
effective sedating agent when used in a prchospital setting for seizures and agitated or 
I . . ~·HI II hi' . . d' 'bl . psyc 10t1c patH:nts . owcver. some recent pu !Catwns m 1cate poss1 e negat1vc 
side effects associated \Vith midazolam and head injured patients. As Davis (200 I) 11 
suggests increased doses of midazolam can be associated with a detrimental outcome to 
patients \V\lll have sustained head injuries. 
2 
This study will primarily examine whether midazolam influences hypoxia and/or 
hypotension d11ring sedation of unmanageable patients in a prehospital setting who have 
sustained a head injury. The majority of patients in this study had sustained a closed 
mild or moderate traumatic brain injury, with a small number of cases having sustained 
a severe traumatic brain injury (TBI). 
3 
1.2.Aims 
To evalUate the effect of midazo!am in patients with a head injury in the prchospital 
setting. 
Ultimatc\y the research will investigate whether midazolam increases the symptoms of 
hypotension and hypoxia in patients with head injuries in a prehospital setting .. 




2. Literature Review 
2.1. Mic.lazolam 
The synthesis of midazolam was discovered by Fryer and Walser in 1976 11. Today 
midazolmn is kno\\ll by the brand names Versed R.. llypnovcl ~ atH.I Dormicum R. 
Midazolam is <t Schcduh: 4 drug (requiring pn:scription) undo::r the Poisons Act \%4 
(\VA). l!ypnovel" is the brand of mid<.~zolam ttscd by paramedics at StJohn Ambulance 
Service W.A. Midazolam is a short acting benzodinzcpinc that induces scdution. 
hypnosis. amnesia and anaesthesia \Vith the c!Tccts on the CNS depending on the dose 
received, the route of administration and the pn:scncc or absence of other m..:dicatinns. 
Aller intrav!.!nous administration at a dose of 5 to lOmg. onsd of S!.!dution will occur 
within 2 to 3 minutes, followed by peak sedation for the individual at 30-60 minutes 
following injection u. Miduzolam has been known to cuusl! an anaesthetic state among 
individuals. llowever, 14% ofp~1ticnts will not reach anaesthetic stat~ with the i.ISL' nf 
miduzolam alone l.t. 
2.1.1. II istory of the implementation of midazolam in pre hospital care in Austrulin. 
Midazolum (llypnovcl~. Roche) has many clinical uses and has bcl!n used not only t()r 
its sedative actions. hut for the managl!ment or seizure activity. back pain and antisocial 
or aggressive behaviours in prchospital settings. From the beginning of April 1997 
NSW paramedics bcgan using midazolum in thc prchospital setting as it was found to 
produce equal clinical effects to those of diazepam. a commnnly used scdati\'e, ''ith 
fl!wcr complications of respiratory dcprL·ssion in pati~.:nt.». Morcov~.:r. miJaznlam has a 
hulflife of 2-3 hours wmpared to a half life of(, lwurs fer diazepam making miJaznlam 
a more appropriate drug to use in prehospit<ll cnrc 7• Thus miJazolam provides patients 
with !~1st actin~; treatment without prolonged sedution u. 
Midazolum was first introduced as a sedating agent at StJohn Amhulanec Service \V.A. 
!Or the manag.ement of fits or scizmc activity in \999. In 2003 midazolam wus 
implcmcnicd as a sl'dating agent ti.x antisoeial or aggre.s.si\"L' hchaYiours in the 
prchospital setting. By 2004 midazolam wa:-. also introdueed as a pain management toni 
for back pain symptoms 15. 17 • Prior to that midazolam's primary usc \\liS as a sedative 
agent during minor surgical procedures in hospital care. Midazol<.un is now widely 
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The structure of midazolam is 8-chloro-6-(2·1luorophcnyl)-l-mcthyl·41-l-imidazo!l.5· 
a][I.4J bcnzodiazcpinc (Figure 2.) and the chemical formula is ClRih:,CIFNJ. The 
compound has a molecular weight of 325.8 and in its non active state it is a solid white 
'l 





f"igw·~ 2. A s/ntc/1/rul il/uslrulion oj111ida::o!um !l. 
Midazolam manufactured for injection is a clear c.olourless or faint yellow solution that 
contains midazolam as a salt together \Vith sodium chloride in sterile water. At a pl-1 
between 2.9 and 3.7 each prepared injection is available in lmg/ml and Smg/ml 
strengths. 
2,1.3. llosagc and Administration orMidazolam 
The dosage of midazolam administered to patients varies depending on the patient's 
symptoms (Table I). The preferred route of administration of midazolam in the 
prehospitul setting is intramuscular. Intramusculur administration has been shown to be 
an easier and safer form of administration for lilting or aggressive patients 7• Alter 
intramuscular administrution the onset of midazolam effects will occur \Vilhin I to 5 
minutes. The time of onset will vury for each individual and will depend on the rate of 
absorption from muscle. The onset of midazolam etlCcts is also strongly dependent on 
an individual's genetic makeup, particularity to the genes coding for drug metabolising 
ability 23•27• 
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Table I. Dosage or midazolam used lOr patients in prcbospital setting 28 
Atlult l>ost· of Mida:.wl11m mg 
Seizures I Omg 
il' h·ai! ur over 6S - ha! f adult dose 
----~ 
Antisocial 1 0-25mg 
-----c~ --
Baek Pain 2.5-Smg 
------
--
Mid~tzolam is absorbed hy as much as 80 to I 00% following intramuscular 
administration and ;tccmding Ill DunJec e/ al (1984)P produces greater sedation, more 
amnesia. a signilicant anti<mxicty cfll:ct anJ less pain at the injection site compared to 
hydruxyzinc or dia1.1...'pam. 
It is important to mention thut cmcrgl!ncy situations arc has~...·d on rapid asscs~mcnt and 
administration or treatment. hence weight is not considered by thL' W.A. Ambulance 
Scrvicl.! Clinical Practice Guiddines ts~...·~...· uppenJix 1) and doses administered to patients 
arc not b<.1sed on the patient's weight. 
2.1A.I)rinu•~· Indications of Mido,zolam in the Prchosptial Setting 
The t\VO primary indications of thl! use of midazolam in W.A. pre hospital Sl.!tting Ufl! for 
seizure activity and anti-social or unnwrmgeabk bdmviour. There is a growing ameunt 
of litcraturl! that suggests that midazolam is an accl!ptablc si!Uating agent used in 
I . I - . . . . "' ,, 1.1 d d db pre 10sp1ta care to treat acutl! se1zure ncttvtty 111 paucnt-.; · ·· · . 1c stu y con ucte y 
RainbO\V ct a/ (2002) 7 suggested that midazo\an1 is morl! cflL-L"tivc than diazepam in 
controlling seizures in childrl.!n in a prdmspitul setting. '\11c study demonstrated that 
there were significantly ll:wer cusl!s of respiratory di.!pression whl:n midazo\am was 
used compared to diazl!pam. /\\so the mean dosage of midazolam administered to 
patients was significantly less than that or diazepam 7 • 
A separate study conducted by McGlone and Smith (200\ )5 indicated that intranasal 
midazolam (0.2mg) is more c!Tcctivc and less invasive than intravenous diazepmn for 
treatment of seizure in children in emergency care. 1\arbord el a/ (2004)9 also found that 
(0.2-0.3mg) intranasalmidazolam is more effective and easier to administer than rectal 
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diazepam for children with acute seizures in the community setting. Moreover, the 
overall time fOr cessation of scizu~~3 in children is quicker with the u.se of intranasal 
midazo\am (0.2mg/kg) than with intravenous diazepam (0.3mg/kg) 4. Shah et a! 
(2005) 10 also suggests that intramuscular midazolam (0.2mg/kg) is safer and more 
effective than intravenous diazepam (0.2mg/kg) in the control of seizures irrespective of 
the type of convulsion and age of the child. Ultimately these studies found that 
midazolam is safe and easy to administer and the time to treat seizures is reduced 
compared to diazepam. 
The second most common use of midazolam is for the treatment of aggressive or 
unmanageable behaviours in patients that may be due to severe illness such as mental 
illness, substance misuse or head injuries. If the patient cannot be calmed by words, 
sedation of the patient may be unavoidable. There arc studies that suggest midazolam is 
a safe and cf!Cctive sedating agent for the control of anti-social or aggressive patients in 
prehospita\ carer;. The TREC (Text REtrieval Conference) Collaborative Uroup8 found 
that administering 7.5mg to 15mg of midazolam consistently sedated aggressive or 
agitated patients for up to t\vo hours. Although haloperidol and promethazim: were also 
used in this study intramuscular administration of midazobm \Vas clearly more effective 
with minimal adverse effects x. Huf et (I{ (2002/ agrees that there arc few adverse 
effects associated with the usc of intramuscular administration of midazolam in agitated 
or violent patients. The dosage or midazolam used in the study by Huf et (1/ (2002/' 
varied from 3-1 Omg depending on the clinical condition of the patient and previous 
exposur-:: to other drugs. 
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2.1.5. Contraindicutions and ~ide cfrccts of Midazolum 
While there arc many studies that support the safety and efficacy of midazolam when 
used as a sedating agent, there arc several side effects which include rcspimtory 
depression as the most concerning 29-31 . Early studies conducted by Dundee e/ a/ 
(1984)13 suggest that intravenous midazolam causes a decrease in tidal volume that is 
compensated for by an increase in respiratory rate. A benzodiazepine antagoni:;t 
flumazenil can reverse the respiratory complications and sedation induced by 
midazolam 6•8•32• 
Other side effects or minor adverse reactions in patients after intramuscular 
administration of midazolam include: headaches (1.3%) and/or local effects at the 
injection site (pain (3.7%), indurations (0.5%). rcJncss (0.5%) and muscle stiffness 
(0.3%) 33 • On rare occasions midazolam provokes hostility and violence instead of 
calming effects in patients 32 . Other adverse reactions reported with intramuscular 
administration of midazolam arc given in Table 2. 
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Table 2. Adverse Reactions of Intramuscular Administration of Midazolam 33 
Complication Type of Reaction 
Respiratory Laryngospasm, bmnchospasm, dyspnoea, 
hyperventilation. wheezing, shallow 
respirations, mrway obstruction, 
tachv moea. 
Cardiovascular Bigeminy. premature ventricular 
contractions, tachycardia. nodal rhythm, 
cardiovascular collapse, vasovngal 
cnisodc. cardiac arrest. 
Gastrointcstitml Acid taste. excessive salivntion, r~.:tching. 
C N SIN curomuse ul ur Anterograde amncsm. hcadm.:he, 
euphoria. confusion. argumcntati vencs~. 
llCfVOlLSlles:.;, agitation, anxiety. 
grogginess, irrit<~bility. restlessness, 
emergence delirium or agitation. 
prolonged emergence from anaesthesia, 
dreaming during emergence. sleep 
disturbance. tnsomnta. nightmares, 
tonic/clonic lllOVCllll.!lltS, muscle trcmor. 
involuntary lllOVI!JllelltS. athetoid 
Jl10\'Cl11Cilts, dinincss, ataxia. dysphoria, 
slt.!_rrcd spcccb.:~~~lH)nia. paril.L'sthcsia. 
Ophthalmic BlurrL·d \ lSIOtl. Jiplopia. nystagmus. 
pinpllint pupils. 1'ydic 111\l\'elll!.!tltS or 
Dermatolt1gic 
+-;~\'elids. di rticl! l.!)~it.U~ JC~~"ing 
I li\'cs. hi\'c-likc ele\'ation at injection 
site. S\\'CJling or rc~.:ling or burning. 
W(lnll\h or cniJncss at injection site. 
L"f~ them a. rash. Jlruri tus. 
-~~----
---
Miscellaneous l:'<.mning. lethargy. chills. weakness. 
continucJ phonation. cars blockct.l. loss 
or balanc(!. \ight-hl.'adedncss. toothache, 
l·aint fccl~mcmatllllla. 
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2.1.6. Pharmacology and Mechanisms of Action of Miduzolam 
The structure of midazulam provides it with lipophilic properties allowing the drug to 
cross lipid membranes. particularly the blood-brain barrier and affect the Central 
Nervous System (CNS) 2 • Midazo!am is also known to act on peripheral nervous tissue, 
resulting in coronary vasodilation and neuromuscular blockages at very high doses 19• 
Midazolam like bcnzodiazepines has an affect on the CNS. There is a scarcity of 
literature available on the specific regions of the CNS that arc affected by midazolam. 
However the mechanism of action of midazolam in general on the CNS is via binding to 
the gamma-wninobutyric acid (GAllA) receptor. GAllA is a naturally occurring 
neurotransmitter round in the CNS 2· 34 • The GJ\BA receptors, membrane bound 
proteins, arc divided into two major subtypes: GABAA and GABAn receptors 19• 
GABAA receptors induce sedation and anti-anxiety effects and arc located in the 
cerebellum and spinal cord of the CNS 35 . GABAB receptors are located in the basal 
ganglia and hippocmnptls. These receptors are associated with muscle relaxation as well 
as memory and learning. 
Midazolam binds to the GABAA receptor. resulting in physiological effects such as 
sedation, decreased anxiety, amnesia, muscle relaxation, anaesthesia and anticonvulsant 
activity 2• This area of interest requires more research and is continually being 
investigated. 
2.1.7. The GAHAA receptor complex 
The GABAA receptor complex belongs to a large family of hetcro·oligomeric ligand-
gated ion channels. The ionotropic GABAA receptor is composed of five known 
subunits that contain recognition sites for various chemical agents. The GABAA 
receptor complex contains recognition sites f(n; GABA ngonists and ant::lgonists, u 
barbiturate binding site. a bcnzodiazepinc binding site. a steroid binding .site and a 
picrotoxin binding site {Figure 3) 12• Uhimatc\y the binding of midazolam to its 
recognition site results in an increased influx of chlorine ions, which result 111 
hyperpolarisation m the post-synaptic membrane and inhibition or ncurotransmission Jh. 
11 
Figure 3. An illustration of the GABA14 receptor complex, showing recognition sites for GABA, 
barbiturate, benzodiazepine, steroid and picrotoxinin 11. 
Benzodiazepines are known to modulate the binding of GABA to the GABAA receptor 
ultimately altering binding in an allosteric fashion 12• Benzodiazepines can act as 
agonists (positive modulators), inverse agonists (negative modulators) or as antagonists 
(blocking both positive and negative modulators), depending on the benzodiazepine 
compound and the subunit composition of various GABAA receptor isofom1s 37• 38 . 
Benzodiazepine agonists binding to the GABAA receptor site will increase chlorine ion 
influx and inverse agonists will decrease chlorine ion flow. Midazolam acts as a 









Figure 4. A schematic diagram ofhyperpolarisation activity 
during inhibition ofGABA J8_ 
. 
When midazolam binds to the GABAA receptor there is an influx of chlorine ions 
resulting in hyperpolarisation activity of the cell membrane (Figure 4) 38 . Ultimately the 
influx of chorine ions suppresses neuron activity at specific neurons in the CNS 
resulting in sedation or relaxation of the individual. 
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2.1.8. Metabolism of Midazol:tm via cytochrome P450 Drug Mctaholising Enzymes 
Midazolam is predominately metabolised by the hepatic cytochroml! P450 drug 
metabolising system. Mammalian cytochrome P450 proteins (CYP450) arc a group of 
haenHhiolate monooxygenases that play a major role in drug metabolism. Cytochrome 
P450 enzymes <tel via an NADPI-l~dcpendent electron transport pathway and have the 
ability to form multiple interactions with a variety of xenobiotie compounds 39• The 
name 'cytochrome P450' is derived from the absorbance spectrum of the haem 
containing protein, characterised by a maximum absorption wavelength of 450nm when 
reduced in the presence of carbon monoxide (CO) 40• The P in CYP450 stands for 
pigment hence the abbreviation, P450 40•41 • 
Midazolam is one such drug that is metabolised by cytochrome P450. Many studies 
suggest that CYP450 enzymes contribute to 70 -90% of the metabolism of midazolam 
in individuals 26· 27 . P450 proteins are categorised into families, subfamilies and single 
cytochrome P450 enzymes. There arc 18 families (CYP1~18) and 43 subfamilies 
(CYPX\~2) of cytochrome P450 found in lwmans 40• Thc predominant form of 
cytochrome P450 is CYPJA, clustered on chromosome 7. Many of these protcins are 
d . 1· . . . I . I 1· d I '· "d '' " Tl . I 1· expressc Ill 1ver tissue, mtestma ep1t 1e mm an t 1e ,.;1 ncy ~. . 1C maJm roc o 
CYP450 enzymcs is to catalyse the phase I reaction of drug metabolism which involves 
oxidation, reduction or hydroxylation reactions, to modify the xcnobiotic, making it 
more easily excreted. /11 dm studies show that fl1ur members of the CYPJA subfamily 
contribute to midazolam clearance in the body; CYPJA4, CYP3AS, CYP3A 7 and 
CYP3A43 2u 1• 
Being a water soluble compound midazolam is carried via transport proteins in the 
blood to the liver where it is metabolised to less activc metabolites. During the first 
phase of mctabolism midazolam is hydroxy Ia ted by CYP450 into three metabolites; 1-
hydroxymidazolam (1-0IIM) (responsible fOr 63% of midazolam activity). 4-
hydroxymidazolam {inactive) and 1 ~hydroxymidnzolam glucuronide ( 1-0llMG) (6% of 
midazolam activity) .w. 4.1-45• The production of !~OHM is the predominant pathway of 
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midazolam metabolism accounting lOr 95% of the process, with only 5% metabolised to 
4·hydroxymidazolmn 45, 
Genetic variations m human population groups exhibit various polymorphisms. 
Polymorphisms with CYP450 genes that code for the multiple enzymes are thought 
responsible for a large proportion of genetic variation in drug metabolism ability and 
sensitivity to drugs. A variation in drug metabolising ability determines \'ihcther 
individuals arc good or poor mctabolisers of alcohol or other drug agents 46• This area or 
research is not completely understood and requires further investigation. 
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2.2. What arc the causes of Head Injuries in W.A '! 
Midazolam is commonly used by paramedics to treat unmanageable p.1ticnts who have 
sustained a mild or moderate hc<1d injury. The di rtCrcnt head injuries assessed within 
this study inciUlh;o: l'rm:tun:s, lacerations, <!brao;;ions, swelling, bleeding, tenderness or 
contusions. 
Road trauma accidents are a growing concern for community and health departments in 
the state of W.A. There was a 26.4% increase in the number of head injury admissions 
to Royal Perth Hospital (RPH) from 2003 to 2004. The 2004 RPH Trauma Registry 
Report sl<tlcs tlmt 48% of adm;ssions of major traumas urc a result or road accidents. Of 
this group. 25% ol' cases sustained head injuries in a motor vehicle at:cident. Other 
major causes of head injuries in W.A. were; 38% as a result of a lUlL 21% struck by an 
object, 6% were involved in motor bike accidents. 3% as pedestrians, 3% as pedal 
cyclists, 1% were sporting or rccre<~tional accidents, 1% were gunshot or stabbing 
accidents and I% were horse riding accidents 47 • 
In 2004 85% of major trauma admissions to RPJ-1 were via ambulance transporl<!tion, 
escorted by a StJohn Ambulance paramedic. Management of pntients with head injuries 
is important to ensure minimisation of secondary brain injury. t-,.ianagement and 
prevention of secondary brain injmy must begin at the scene of the accident. To ensure 
suflicicnt management and prevt:ntion of secondary brain injury early detection of 
injury. rapid tmnsportation to hospital and resuscitation lo prevent deterioration in the 
. . d h h d' ~R ~'I palicnt arc reqwre y t c pamme 1cs . 
The Brain Injury Association of W .A. Inc states: "Bruin Injury is not a disease. or 
something you mn •· catch". Brain Injury is de.fined liS a los_.,. t~l hl'llin jimction, aw . .,·ed 
hy accidents. poisoning. stroke, hrain 11/IIWUrs. infi:i.'l ions or lack t!/' oxygen 50 " 
(Tnblc 3). 
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Table 3. Causes of !lead Injuries 50 
Cause Description 
Accidents Road accidents, Sport and/or work 
related. assaults. shaking your child. 
Poisoning Drinking to much alcohol. overuse or 
prescribed drugs. usc or illegal drubs, 
petrolund chemical snining. 
Stroke Rupture of a blood vessel Ill the brain, 
block~c of hlood supply to the brain 
Brain tumours CanccrOllS or non·canccrous 
Infections Meningitis. Enccphnlitis 
Lack of oxygen Ncar drowning. severe asthma attack, 
lack of blood flow to the brain (heart 
attack). 
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2.2.1. How is the brain injured? 
Traumatic brain injury (TBI) is a major problem with both high mortality and high 
morbidity. Almost 2% of Australians have acquired head injuries with resulting 
disabilities 5(1. Injury to the brain may occur at the time of injury (primary injury) and/or 
subsequently dL1C to cerebral ischaemia (secondary injury). llypotension and hypoxemia 
arc causes of secondary brain injury. Many studies have confirmed that outcomes 
following traumatic hrain injuries result in individuals experiencing cognitive and 
behavioural symptoms dt1ys. weeks even months after the trauma. Ranging symptoms 
may include headaches. vertigo, sensitivity to bright lights and/or noise. blurn:d vision. 
insomnia. restlessness. reduced concentration and memory probh:ms, irritability. 
IUtiguc. an.xiety and depression 51 •57 • When brain injury has occurred it is crucial lOr 
prehospital management to focus on preventing secondary brain injury and minimising 
I I f .t'J 'iH '\9 t1c c lances o a poor outcome · · · · . 
Paramedics at StJohn Ambulance encounter many incidents of head injured patients. 
The majority of patients in this study have sustained a mild or moderate 1'[31. Mild or 
moderate TB!may involve the head being injured as a result of a fractures, lacerations. 
abrasions, swelling. bleeding, tenderness or contusions. 
18 
2.2.2. Glasgow Coma Sc:llc (GCS) 
The Glasgow coma scale (GCS) is the most widely used scoring syst~m in ass~ssm~nt 
of the level of consciousness for patients \Vith head injuries in a prchospitul situation. 
'I he Glasgow coma scale score provides a simple measure of patients' level of 
consctousncss with u high degree of reliability. h is simple and easy Ill use: its 
observations arc based on eye response. verbal response anJ motor response (Table 4 ). 
The Gl<~sgO\v coma scale score provides paramedics with an asscssml.'nt tool for 
patients' conscious state which enables satisfactory nwnagcmcnt of the p. :...:nts' injuries 
prior to hospital admission. 
Table 4. Glasgow Coma Score table 3 
Eye Opening (E) Verbal Response (V) Motor Response (Ml 
4 -- Spontaneous 5 Norrnal Convcr:->atinn 6 Normal 
3- To voice 4 = DisoricntaJcd con\-crsation 5- Localised tu p<til\-
2- To pain 3- Words. hut not coherent ~- \\'ithdr<ms to pain 
1- None ::! -No \\ords. only suunds 3 = Dcconicah: pu~\ure 





2.2.3. Mild Tmumat11L' Brain Injury 
A mild tnmmatic bruin injury can be defined by any of the following: ( 1) Direct contact 
to the hend, due to outside forces or to accc\eration/decclcration trawn:.. (Ca1is). (2} Loss 
of consciousness (LOC) expcricnct:d by the individual is usually brief, lasting seconds 
to minutes, and in some cases no Joss of consciousness is c.xp!..'rienccd; only a dazed 
consciousness occ 1rs. (3) The paticnt"s evaluated UCS is 13 to 15. Only a GCS score of 
IS represents a trul mild TBL (4) Confusion along v . -ith amnesia is experienced by the 
patient Justin~~ minutes to a few hours. \vhether or not there arc periods of 
unconsciousness. (5) No !i.1ca\ signs an: pr·:scnt in the patient; the patient may also have 
I I . b d' I . I . b . ~>o hi a pa e comp ex1on, e mp 1oret1c am expenence nausea or c at:tXIC . 
2.2.4. Moderate Traumatic Brain Injury 
A Moderate Tmumatic Brain Injury (TBl) has a GCS grading of9 to 13. Moderate TBI, 
like mild TBJ. can result in the head being i11jurcd from fractures, lacerations, abrasions. 
amnesia or contusions. individuals with n modemte TBI pose a greater risk of 
developing secondary brain injury. Fifty percent ol'mndcrate Tl3J patients suffer long-
term disabiiitics 62 • 
2.2.5. Severe Traumatic Bruin Injury 
A severe TBI has a GCS score orless than 9. The causes of severe TBI arc identical to 
those of mild TBL \.Vith the exceptions ofwhiplasl' ~md assaults that occur more 
commonly \'.ith mild TBl ~>o. Severe TBI occurs 1l:om considerable forces exceeding the 
skulls tokranc.c; the greater the force the greater the injury. This may include a fracture, 
laceration. abrasion, amnesia or contusion, htm~ver to a greater degree of severity. 
Other indicators of severe Till may be continual brain stem rc!1cx posturing, increased 
intracranial pressure (ICP). hypertension and incrc<:~scd body tcmpcmture 63• 
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2.2.5.1. Skull Fractures/Direct !lead lltiury 
Skull fractures arc often catt.!goriscd as basilar, linear, depressed or comminuted skull 
fractures that arc either open or dosed. Skull fractures arc often the result of a force that 
penetrates or fractures the skulL causing thl.! skull to bend imvards at the site of impact 
d I . d d I . f. "' o· I d . . . an at t 1c same tunc curve out\vur s aroun t 1c s1tc o 1m pact . 1rcct lea lnJuncs 
that result in fractures may occur during a motor vehicle accident, falls or assaults i.e. 
direct strikes to head. 
Fractures to the head can also occur at the base of the skull (Anterior fi.1ssa fractures). 
An anterior fossa fracture inr.:re.:tscs damage to cranial nerves and vessels that result in 
rhinorrhea or epistaxis (cerebrospinal fluid drainuge from the nose), periorbital 
ecchymosis and anosmiil. (crnniol nerve one damage) or visual defects (cranial nerve two 
damage). Injuries involving the middle car arc a result of po~tcrior foss..'lc fractures. 
Fractures to the temporal petrous bone can result in blood drainage from the ear ~>J. 
2.2.5.2. Dislocatinnsllnr.lircct I lead Injury 
Indirect head injury involves injury to brain tissue as a result of severe whiplash or 
··shaken baby synJromc"'. This form of trauma to the brain results in disruption of nave 
cells and their axons leading to permanent brain damage or complications u5• 
2.2.5.3. Contu5ions/Swclling/Di1Tusc Axonal injury 
Diffuse axonal injury causes brain tissue damage that is often dillieult to detect and is 
often the cause of indirect hc.:td injury. The lll:n·c cells located in grey matter of the 
brain communicate with the white matter. axon nerve tracts. Sudden stretching, tw·isting 
or jolting of these nerve tracts can lead to coma or brief loss of consciousness. Diffuse 
axonal injury results in microscopic damoge to brain tissue that can not~ visualised on 
Computer Tomograph (CT) or Magnetic Resonance Angiography (MRA) scans but 
may appear on a Single Photon Emission Computed Tomography (SPEC!") scan 6 ~. 
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2.2.5.4.11ypoxic/Anoxic Head Injury 
The bmin weighs approximately 2% of our body weight, yet consumes 20% of the 
body':; oxygen supply. Thacfon.:. the brain is more susceptible to injury if there is 
insufli:-:ient oxygcn supply. Hypoxic brain injury is a decreased supply of oxygen to the 
brain and anoxic hrain injury is thl! absolutl! lack of oxygen. lnju1y to the brain will 
often set in alter a lack of blood llow to the brain and is also kno\.\'!1 as ischacmic insult 
"' 
The areas of the brain a!kctcd by rl.'duccd oxyg~.,:n supply include the cerebral and 
cerebellar regions. in particular basal ganglia. Regions of the bruin that arc also 
sensitive to lack of oxygen include the Purkinjc librcs of the cerebellum and paricto~ 
.. I ' I h' 1'6 occ1p1ta cortex anu t 1!.~ 1ppocampus . 
2.2.5.5. Secondary '1\ ... pcs or lle,1d Jnjuri{.'S 
Secondary brain injury is often the result of the head being injured minutes, hours or 
days a!ier the initial insult. The cause of this type of injury \Vill vary from intracranial 
hacmatomas. intracranial infection, epilepsy and systemic hypoxia to hypotension. The 
most common secondary brain injuries sustained by patients in this study are 
intracranial haematomas. 
2.2.5.6. Intracranial Hacmatomas 
An intracranial hacmatoma is a localised collection of blood due to a tissue injury or 
tearing of blood vessels. The Jura is membrane that covers the bmin and spinal cord. 
Blood clots that develop between the skull and dura mater arc known us epidural 
haemutonu.Js. A blood clot that develops hetwl!en the dura mater and the brain is called a 
subdural haematoma ~ 0 • 
There arc a number of intracranial hacmatomas identiJied in the brain all arising from 
various physiological complications. Thl!sc haematomas may be located in various 
regions of the brain: Frontal, parietal, temporaL occipitaL optic nerve, ccrcbe\la-pontinc 
angle, brain stem, hypothalamic and pituit<Jry. posterior fossa 66• 
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Only patients that sustained a closed skull fracture and a GCS between 14 & 15 (mild 
TBI) 9 to 13 (moderate TBI) and a GCS < 9 (severe TBI) were used in this study, with 
the majority having sustained a mild to moderate Tl31. 
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2.3. Pathophysiology of Head Injuries 
Fundamental processes occur during bead injuries which can culminate in cell death. 
These processes include the release of the excitotoxic amino acids, aspartate and 
glutamate. production of free radicals. and increased levc\s of lactate and hydrogen ions. 
The final pathway of the process involves the entry of calcium ions into the cells. which 
results in cell swelling. S\\·elling \Vithin the cranium results in an increase in intracranial 
pressure (ICP) and a reduction in ccrehral perfusion pressure (CPP =the mean arterial 
blood pressure- intracranial pn.:ssurc). What follows is cerebral ischaemia and reduced 
delivery of oxygen and glucose to the tissue, provoking further acidosis ami the n:lcase 
of free radicals ~' 7 . Studies have shown that brain ischaemia is the predominant cause of 
complicating traumatic hrain injury bM-?I_ 
2.3.1. Uypoxill and Hypotension in llcnd Injuries 
Injury to the CNS in head trauma leeds to a chain of physiological events that lead to 
secondary brain damage. lnsufticicnt oxygen supply to the brain after injury to the head 
is kno\vn to result in tlclctcrious effects. Inadequate oxygen to brain tissue may occur 
from arlt.::rial hypotension. low haemoglobin concentration and decreased oxygen 
saturation. Most of these factors arc the result of secondary brain damage that occurs 
from cxtracranial injuries. causing respiratory failure and blood loss 72 . 
The treatment of hypoxemia and hypotension often occur at the scene of injury. 
Ventilation of the patient ensures th::n both hypoxemia and hypotension arc controlled 
prior to patient arrival at hospital. A decrease in oxygen saturation of less than 90% 
suggests the patient has reached a hypoxemic state, (oxygen saturation (P02) measures 
of less than (l() mmllg arc dcfinl'd as hypoxic). Studies by Godwin el of (2005) 30 have 
shown that bcnzodiazt.:"pincs nnd opioids used in sedation and analgesia increase the 
patient's chances of developing hypoxemia. Chestnut et a/ ( \993) 73 reported that 
hypoxia occurs in 45.6% of severely head-injured patients and has a signilicunt 
influence on patient mortality. 
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Hypotension is a lowering of blood pressure; a systolic blood pressure of less than 90 
mm J-Ig. ~ 6 In a recent article Choi et al (2004) 74 found that doses of 0.2-0.3mg of 
midazolam caused hypotension in 20% of intubated patil..!nts in a pr!.!hospital setting. 
Rapid administration and increased doses of midazolam may also be associated with 
hypotension 30. Many studies have suggested that midazolam causes arterial 
hypotension. especially in elderly and haemodynamically comprised individuals 74' 76. 
The biochemical mechanisms behind midazolam-induccd hypotension arc not 
completely understood. llowcvcr. discussion by Jones et a/ ( 1979) 77 and Reves et a/ 
( \984) ?H suggest that the negative inotropic ciTccts. reduced vascular resistance n 1111 or 
reduced sympathetic activity HI may account for midazolam-imluccd hypotension. 
Moreover other studies suggest that midazolam directly relaxes vessel tone and causes 
"Jh · H27~8l artcrm ypotcns1on -' ·. 
This study will examine the relationship between midazolam usc in a prehospital setting 
for patients with head injuries. There will be particular focus on whether midazolmn 
contributes to increased symptoms of hypoxia and hypotension. 
There is a growing amount of literature that suggests midazolam contributes to 
increased symptoms of hypoxia and hypotension in individuals. The study hy Chestnut 
eta! (1993) 7.1 clearly showeJ that hypoxia anJ hypotension lcnJ to an increase in 
mortality of 50% in patients sullCring from severe head injuries. This raises an 
important question: if midazolam contributes 1.1 increased hypoxia and hypotension in 
patients, why is midazolam being administered to individuals \VIm have sustained head 
injuries when hypoxemia and hypotension me common complicutions associated with 
head injured patients'? Therefore, this study will be assessing whether midazolam dues 
increase the symptoms of hypoxia and hypotension in patients with head injuries. 
25 
2.3.2. Glasgow Coma Scnle Assessment for Traumatic Brain Injuries in the prchospiml 
setting 
Western Australian paramedics usc the Glasgow Coma Scale (GCS) to categorise the 
severity of Traunwtic Brain Injury (fl31) in individuals. A mild TBI cnn include 
fractures, Jaccrutions. abrasions or contusions. More commonly mild TBI patients 
include loss of consciousness (LOC), amnesia, vomiting, headaches or changes in 
mental swtus at the time of trauma (Figure 5). A GCS score of 13 to 15 is used to 
categori:-.c a mild TBI 62 . A mild head injury is oltcn ~ubdividcd into categorises of low 
. k d' . k I . I . k 84 ns ·,me mm ns ·or 11g 1 ns . 
Mild TBI (GCS 14-15) 
Low Risk Moderate Risk High Risk 
GCS 15 without LOC, GCS 15 with any of GCSof14or15with 
amnesia, vomiting or LOC, skull fracture and/or 
headache amnesia, vomiting, or neurological deficits 
headache 
Flj.:urc 5. ,J!Rorithm of cul!');l!ries of,\ti/J /HI (CiCS) R"lm.!s 85 
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2.3.3. Patie-nt Assessment in the prchospilal setting 
Any assessment of TBI management in a prehospital setting requires a valid tool. The 
visual nnalogue scale (VAS) and verbal numerical response scale (VNRS) arc two vulid 
assessment tools used by param~dics at StJohn Ambulance Service W.A. These tools 
ensure a quick, simple, reliable and valid assessment of patient's injuries. 
2.3.3.1. Visual Analogue Scale (VAS) 
The visual analogue scale consists of a vertical or horizontal line. 1 Ocm in length with 
scale~ of no pain and worst pain at each end (Table 5). The respondents mark a point on 
the line to represent the intensity or his or her pain. The VAS simplicity, reliability and 
validity allow the puin assessment tool as an optimal device for describing pain levels 
for patients x". The limitation surrounding the accuracy of the VAS tool is that some 
individuals may be visually impaired. suffer from motor deficits or cognitive 
impairment. This may occur particularly in elderly individuals or trauma cases. The 
other limitution found with the VAS is the error rate within the scale of approximately 
20mm H7• 
wom.p11n 
2.3.3.2. Verbal Numerical Response Scale (VNRS) 
The VNRS has the bro<Jdcst application in the prehospital selling. Paramedics ask the 
patient to describe the severity of their pain on a scale from zero (no pain) to ten (most 
severe pain). The patients' level of pain is recorded and treatment is administered where 
appropriate 87. 
Limitations surrounding both the VAS and VNRS tools arc that individual 
interpretations of pain intensity and severity will vary slightly. llowevcr both these tools 
are used for assessment of traumatic brain injury in a prehospital setting and nppropriatc 
assessment is necessary to ensure effective treatment x<~. 
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3. Methods 
The patient cohort comprises retrospective data collected from (unidentified) patient 
cmc records between January 2001 and February 2006 from the database at StJohn 
Ambulance Service W.A. (sec appendix I -Patient Care Record sample sheet). Patient 
care records for all cases that wer~ treated with midazolam and sustained a head injury 
were used and compared to patient care records of cases that had sustained a head 
injury. but did not receive midazolam. The patients that did not receive midazolam 
(non-miduzo\am) for treutmcnt was lJscd as the control group in this study. 
Ethical approval for the projed was given by Edith Cowan University Ethics 
Committee. St John Ambulance Service W.A. also gave permission for the usc of 
unidentified patient care n:cords to CP!lduct the research. 
Physiological parameters were taken from p<Itient care records to assess whether 
midazo\am inlluenccs hypoxia or hypotension in head injured patients and a comparison 
of these physiological parmncters was made with patients who had sustained a head 
injul}' and did not receive midazolam (sec appendix- 2). 




3. Glasgow Coma Scale (GCS) which determines classification of head injury. Mild 
Tl31 == 15 to 14 GCS. moderate TBI == 9 to 13 GCS and severe Tl31 ,._ < 9 GCS 
4. Systolic Blood Pn.:ssurc [ initia 1 rending (Sl3P 1) & final reading (SBP2)j 
5. Pulse Rate per minute [initial reading (PR 1) & !ina\ reading (PR2)J 
6. Respiration Rate p..:r minute [initial reading (RR I) & final reading (RR2)J 
7. Oxygen Saturation in mm llg [initial reading (Pa02 1) & llnal reading (Pa012)] 
Each physiological parameter SBP\, PRL RIO and Pa021 was recorded by paramedics 
on arrival at the scene during initial assessment of patient and prior to administration of 
midazolam or fi.1r the nun-midazolam cases (control group) paranu:h..•rs were recorded 
by panuncdics on arrival at the scene during initial assessment of the patient The !ina\ 
reading for each physiological parameter, Si3P2. PR2, RR2. Pa012. was recorded by 
2R 
paramedics approximately 5-\0 minutes ailer initial administration of miJazolmn or for 
the non-midazolam cases upproximatcly 5-l 0 minutes after initial assessment. 
llypotension in the individual was determined after midazolam administration where 
:;ystolie blood pressure (SUP) decreases to 90 nun 1\g or less \Vitb an initial SBP greater 
than 90 mmllg. Other variables considered includ!.! where a further decrease in SBP of 5 
mmllg or more in patients is observed with an initial SI3P higher than 90 mmllg. Where 
SBP cannot be obtained other indicators of hypotension (decreased pulse rate and 
respiration rate) wen: tabu\nted and examined. 
To determine whether a patient has reached a hypoxemic stale, pulse oximetry is used to 
measure oxygen saturation. A decrease in oxygen saturation or less than 90% suggests 
the patk.nt has reached a hypoxemic state 30 . Readings of less than 60 P02 mml-lg will 
designate hypoxia. Where readings of oxygen s:Huration cannot be obtuined, respiratory 
distress in the patient was tabulated and utilised for this study. 
Statistical comparisons of the parameters \Vcre undertaken using the Statistical Package 
for the Social Sciences (SPSS) sofhvare version 14 (SPSS lncorporat~.:d Inc.). Analyses 
were conducted on the study population and subsequent analysis was conducted by 
dividing the study population into categorie-s of gender (mule and female). age (less than 
35 years and over 35 yeurs) and head injuries (mild Till, mod~.:ratc TBI and severe TI31). 
Data was inserted into the SPSS spread sheet \'lith the following parameters recorded: 
age. genJcr, category of TBI. wh~.:thcr patients had received treatment of midazohun or 
no trcatnwnt, putients systolic blood pressure readings prior to treatment (initial 
reading). patients systolic blood pressure uftcr trcutment (linal reading). For the patients 
that did not receive tn::atnwnt the initial readings were recorded as initial and tina\ PaCh 
reading. initial and tina! pulse rate readings. initial amllinal respiration rail! r~.:adings. 
A box plot test was us~.:d to determine normality between physiological data sets (sec 
appendices 3 to 30). All data was normally distributed, hence lndepcndl!nt Sample 
Tests. Le\"l!nes"s Test for Equultty of Variances and Paired Sampll! T-Test comparisons 
\VCre used to determine stutisticul significance between pairs of physiological 
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parameters; Sl3Pl-Sl3P2. PR l-PR2. RR l-RR2 and Pa02 l-Pa022. Additional analysis 
was conducted on mild TBI, modl.!ratc rm and severe TI31 using Mil:rosoll Excel 
Studcttl<; t-test. Signi!i~anee was determined with one-tailed distribution and paired two-
sample equal/unequal variance. 
The main limitation of the study was the dilli~ulty in obtaining prc-midazolam 
physiological measures from treated patients. Where a patient is uncontrollable or 
aggressive. obtaining measures or pulse rate, blood pressure or oxygen saturation values 
is extremely diflicu\t if not impossible. In a situation like this the puramedics' primary 
concern is to sedate the individual so no further injury to the patient or anyone else 
occurs. Therefore records of puticnts' initial physiological measures, immediately prior 
to the administration or midazolam. muy result in restricted data validity. Anothl.!r 
limitation was incompktc patient care records. Limiting the study to complete patient 
care records i1wluding the above criteria sewrely restricted the number of cases for the 
study and minimised the study population from 4500 to 96 . 
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3.1. Methods for AnHI,ysis of Results 
The unalysis conducted in this study included the following: 
1. An analysis of \'·.'hcthcr midazol::m1 inllucnccs hypotension in patients with a head 
injury. The physiological parameters used to determine symptoms of hypotension arc 
systolic blood pressure. respiration rate and pulse rate. 
2. Analysis ofwhctht.·r midnzolam inlluenees hypoxia in patients with a head injury \vas 
determined by using the physiological parameter oxygen saturation. 
The approaches used to determine these outcomes were: 
a) A statistical comparison between the initial reading for midazolam and non-
midazolam \vas conducted. The variables used to determine whcthcr thcre is a 
significant difference bctwccn initbl midazolam and initial non-midazolam are: systolic 
blood pressure (SBP I). respimtion rate (RR I) and pulse rate (PR I). 
b) An analysis for significant difference between the initial and final SBP l-SBP2, RR 1-
RR2 and PR I-PR2 readings for the midazolam cohort. 
c) An analysis for signilieunt dir!Crence bctwecn the initial and final SBP1-SBP2, RR1-
RR2 and PRI·PR2 readings for the non-midazolarn cohort. 
d) A cnmparislln of the statistical signiticant diiH::rencc for the final SI3P2, Pa022, PR 
and RR reaJings between the midazolam and non-midazolam cohorts. 
c) An analysis for signiliL'ant difference between b) und c) wus conducted. Is there is 
signilicant dilll:rencc between the initial and linal rcaJings for midazolam compared to 
the initial and tina! readings for thc non-mid<lzolam cohort. 
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3.1.1.1,:tticnt cohorts 
The study population includes a total of 96 patients. The m~jority of patients had 
susl<tined a mild to moderate heud injury. The study population included a total of 56 
patients with a mild TBL 25 puticnts with a moderate TBI and 15 patients categorised as 
su!Tering from scwrc TBI (Table 5). Of the 96 patients, 49 received midazolam li1r 
st:dating puip~,:~cs and 4 7 patients wert: not treated with midazolam. The 4 7 patients not 
treated with mklazolam were used as the control group. 
T:1blc 5. Number of cases for each catl.!gory of Tl3\ for midazolam and 
non-midazol·tm cohorts 
' 
Mild Tl31 Moderate TUI Severe TBI Total 
midazolam 19 16 14 49 
38.8% 32.7% 2R.6% 100% 
non-rniduzolam 37 9 I 47 




58.3% 26% 15.6% 100%1 
The total number of males and females for the study included 52 malt:s and 44 females. 
The number of males and females in the study population for the midazolam cohort 
consisted of 34 males and 15 females. In the non-miduzolam cohort there were a total of 
18 males and 29 femule<: (Tublc 6). 
Table 6. The number of nnlt:s ·md females in the studv population 
' ' 
male female Total 
midazolarn ]4 15 49 
69.4% 30.6% 1 ()() % 
--cc·--· 
non-111 idazolam 18 29 47 
(control) 38.3% 61.7% 100% 
Total 52 44 96 
54.2% 45.8% 100% 
32 
The number of cases in each age group is provided in table 7. Fur the midazohun cohort 
the majority of patients were between the ages of 16-25yrs (21.3%), 26-JSyrs (27.7%) 
and 36-45yrs (23.4%). In the non-midazolam cohort, the majority of patients (38.3%) 
\vcre 66yrs and older. There were two pntients where the age group was not n.:corded by 
paramedics. 
a e . t\_gc Dt.::mo~r~lliCS ol 11e, tu v oru at1on 
I ,_ II· 16- 26- 36- 46- 56- 66yrs Total 
T bl 7 I" . I S d P I . 
I Ovrs 15vrs 25\'TS 35\T~ 45 'TS 55vrs 65vrs older 
midazolam 0 0 10 11 ll 5 I 7 47 
0% 0% 21.3% 27.7% 23.4% 10.6% 2.1% 14.9% 100% 
--- '--;-· 
non-midazolarn I 2 9 5 J 2 7 18 47 
(control) 1.1% 4.3% 19.1% 10.6% 6.4<Vo 4.3% 14.9% 38.3% lOO"l'o 
total I 2 19 18 14 7 8 ,. _, 94 
1.1% 2.1% 20.2% 19.1% ]t\.9% 7.4% 8.5% 26.6% 1 ()()% 
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4.0. Results 
4.1 Analysis of Midazolam/Non midazolam cohorts 
4.1.1 Statistical analysis of systolic blood pressure 












Initial Reading Final Reading 
MEANS 
Figure 7. Means and Standard Error of Blood Pressure (SBP) for midazolam and non-
midazolam groups 
Table 8. SBP summary of means ± SE for midazolam and non-midazolam cohort 
Initial Reading Final Reading Mean decrease Sig. 
(SBPl) (SBP2) (SBP 1-SBP2) (p) 
Midazolam (n = 49) 123 ± 3.4 117 ±3.5 5.5 ± 2.45 0.029 
no midazolam (n = 47) 130 ± 4.4 128 ± 3.9 2.2 ± 0.86 0.015 
Error bar = ± SE (Standard Error) of the mean 
The mean decrease between SBP1-SBP2 in patients for the midazolam cohmt is 5.5 ± 
2.45, compared to a mean decrease of 2.2 ± 0.86 in SBP 1-SBP2 for the non-midazolam 
cohoti. When comparing the statistical differences between these means there is no 
statistical significance between the mean SBP } ecrease of the midazolam cohort to the 
mean SBP decrease of the non-midazolam cohort. 
a) When a comparison was made to determine whether a significant difference was 
present between the initial SBP for the midazolam and non-midazolan1 cohotts (not 
shown in table format); p = 0.150 (as calculated by the SPSS Levene' s Test for equality 
of variances). When p< 0.05 there is a statistical significant difference between these 
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groups. lienee, then! is no signilicant difference between the initial SUP readings for 
midazolam and nmHnidazolam cohorts. 
b) WhL"n comparing the signilicant di!Tcrencc between the initial and final SlW reading 
for the midawlam cohorts; p = 0.029. When p< 0.05 there is a statistical signiticant 
difference between these groups. In this c<.t:-.c there is a statistical signiiicnnt difference 
between the initial reading (SI3Pl) and !ina\ rcadi~1g (SBP2) for the midl'zolam cuhorts. 
The tirllll SUP reading is signilicantly (p < 0.05) lower than the initial SBP reading. 
c) When comparing the significant dillCrcncc \x.'t\Vt.."Ctl the initial and tina\ SBP reading 
for the non-midazolam cohort; p == 0.015 when p< 0.05 there is statistical di rrl'rcnce 
bet\vcen these groups. In this case there is a statistical signilicant dilfcrence between the 
initial reading (SBPl) and final reading (SBP2J for the non-midazolam cohorts. The 
tina\ reading is signilicantly {p < 0.05) lower tlum the initial n:ading. 
d) When comparing the statistical signilieant difference for the final SBP reading 
between the midazohun and non-midazolam cohorts; p == 0.035 \vhen p < 0.05 there is a 
signi!icanl di!TerL'llCL' between the two groups. Therefore. there is a signilicant {p < 
0.05) difference bt.:twecn the tina\ SBP reading \()r the midazolam and non-midazolam 
cohorts. 
c) When a comparison \Vas made between the diiTcrences for SBP\-SBP2 for the 
midazolam and non-midazolam cohorts i.e. the statistical di!Terence bcl\vecn the 
diJTerenccs p "" 0.(l76; when p > 0.05 there is no statistical significance between the 
initial and tina! SBP rcuding bct\vccn the midazolam and non-midazo\am cohorts. i.e. 
there is no stutistical signilicant di!Tcrencc between the di!Tcrcnccs b) und c). 
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4.1.1. Statistical Analysis of Oxygen Saturation (Pa02) 
.--------- ---- -- - --- - - -----, 
OXYGEN SATURATION (Pa02) 
• midazolam 
c no midazolam 
initial Reading . Final Reading 
MEANS 
Figure 8. Means of Oxygen Saturation/or midazolam andnon-midazolam groups 
Table 9. Pa02 summary of means ± SE for midazolam and non-midazolam cohort. 
Initial Reading Final Reading Mean increase Sig. 
(Pa02l) (Pa0z2) (Pa02l- Pa0 22) (p) 
rnidazolam (n = 49) 95.3 ± 0.7 97.1 ± 0.5 1.8 ± 0.472 0.000 
no midazolam (n = 47) 96 ± 0.5 98.7 ± 0.2 2.6 ± 0.443 0.000 
Error bar =± SE (Standard Error) of the mean 
The mean Pa02 increase for the midazolam cohort is 1.8 ± 0.472 after treatment with 
midazolam. The treated patients mean Pa02 readings do not reach 98%. For the non-
midazolam cohort there is a 2.6 ± 0.443 increase in Pa02. Both midazolan1 and no 
midazolam patients received oxygen supplementation during treatment. When 
comparing the statistical differences between these means there is a statistical 
significance between the mean Pa02 increase of the midazolam cohort to the mean 
Pa02 increase of the non-midazolam cohort. 
a) When comparing the significant difference between the initial Pa02 for both 
midazolarn and non-midazolarn cohorts (not shown in table format) ; p = 0.394 (as 
calculated by the SPSS Levene' s Test for equality of variances). When p > 0.05 there is 
no statistical significant difference between these groups. Therefore, no significant 
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difference between the initial Pa02 readings for midazolam and non-midaw\am cohorts 
was seen. 
b) When comparing the .significant dilTercncc between the initial and final Pa02 reading 
for the midazolam cohorts; p = 0.000 \Vhen p< 0.05 there is a statistical significant 
diOCrence between theses groups. In this case there is a statistical signiticant dif!Crcncc 
between the initial n.:ading (Pa<hl) and tina\ rcad.ing (Pa022) for the midazolam 
cohorts. The tina\ reading is si.;;.nificant\y (p < 0.05) higher than the initial reading. 
c) When comparing the signilicant difference bct\\'Cl'll the initial and tinall'a02 reading 
for the non-midazolam cohort: p == 0.000 when p< 0.05 there is statistical diff~rencc 
between these groups. In this case there is a statistical significant differ..::ncc between the 
initial reading (Pa02 1) and !ina\ reading (Pa022) for the non-tnidawlam cohorts. The 
final reading is signilh:antly (p < 0.05) higher than the initial reading. 
d) When comparing th~ statislical significant difference for the final Pa02 reading 
between the midazolam and non-miJazolam cohorts. Using Independent Samp!C's T-
Tcst, Len:nc 's test tOr Equality of Variance. equal variances assumed. p == 0.0 I 0 when p 
< 0.05 there is a significan! difli:rence between the two groups. Therc!'ore. there is a 
significant (p < 0.05) difference between the final Pa02 reading for the midnzolam and 
non-midazolam cohorts. 
c) A statistical comparison between Pa02 1-Pa022 mitlazolam ar,d Pa021-Pa022 non-
midazolam cohorts; p = 0.009 when p < 0.05 there is a !'itatistical significance between 
the initial and tina\ Pa02 reading between the midazolam and non-midazolam cohorts. 
i.e. there is a statistical significant difference between 1he differences b) ami c). 
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4.1.3. Statistical Analysis of Respiration Rate 
- - - - --- --- - - - - --- - - - --- ------, 









In itial Reading Final Reading 
MEANS 
• midazolam 
Figure 9. Means of Respiration Rate for midazolam and non-midazolam cohorLs 
Table 10. Respiration Rate summary of means ± SE for mida:z;olam and non-midazolam 
cohort. 
Initial Reading Final Reading Mean decrease Slg. 
(RR1) (RR2) (RR1-RR2) (p) 
midazolam (n = 49) 23.8 ± 1.0 21.3 ± 1. 1 2.5 ± 0.929 0.009 
no midazolam (n = 47) 19.4 ± 0.5 18.9 ± 0.4 0.425 ± 0.171 0.017 
Enor bar = ± SE (Standard Error) of the mean 
The mean decrease for the midazolam cohort is 2.5 ± 0.§>29 resp per mm after 
midazolam administration. Whereas, the mean decrease for the non midazolam cohort is 
0.425 ± 0.171 resp/min with no treatment administered. When comparing the statistical 
differences between these means there is no statistical significant difference between the 
mean RR decrease for the midazolam cohort to the mean RR decrease for the non-
midazolam coho11. 
a) When comparing the statistical significant difference for initial Respiration Rate 
(RR1) between midazolam and non-midazolam cohorts (not shown in table format); p = 
0.000 (as calculated by the SPSS Levene's Test for equality of variances). When p < 
0.05 there is a statistical significant difference between the groups. In this case there is a 
significant difference between the initial RRl readings for midazoJam and the initial 
RRl reading non-midazolam cohorts. 
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b) Wh~n comparing the significant diff~renc~ bctw~~n the initial and final RR reading 
for the midazolam cohorts; p = 0.009 when p< (J.05 there is a statistical signilicant 
ditli:rcnL'l:' hl'tWCL'n the groups. In this case tberl' is a statistical signilicant di!Tercncc 
lletwc~n the initial rL·ading (RRl) and finn! reading (RR2) for the midazo!am cohorts. 
"lltc final reading is signilicantly (p < 0.05) lower than the initial reading. 
c) When comparing th~.: signilicmtt dillCrcncl' hL'IWL'Cit the initial and Jinal RR reading 
for the noJHttidal.lllam cohort: p = 0.017 \\hen p< 0.05 there is a statistical di!Terencc 
bi..!tWcen the groups. In this C<.LSC there is a statistical signilieant dirti:rL·ncc hl'twecn the 
initial rl..!ading (\{R I) and lina! reading tRR~) li.1r the non-miduznhun cohorts. The finn! 
reading is signilicantly tp < {l.05) lmH:r than the initial rl..!mling. 
d) \\'hen cnmpanng the statistical signilicant difti:n.:nce for th~ tina\ RR rt:ading 
bd\\cen the rnidawlam and non-midazolum cohorts; p = 0.064 when p > 0.05 there is 
no signilicunt dilll:n:n~o:t: h.:twecn the two groups. Therci!Jrl..!. there is no signilicant (p > 
0.05) dirtCr.:ncc hctwccn the tina\ (RR2) rt:ading for the midazolam and tina\ {RR2) 
reading fur non-midaw\am cohort. 
c) When comparing the di!Terl..!nces bctwel..!n RR I-RR2 midazo!am and RR l-RR2 non· 
miJazolam CllhOriS" p = 0.3\6 \\hen p > 0.05 there is no Statistical signilicance between 
the initial and Jinal RR rl.'ading het\ve~n midazolum and non-midazolum cohorts. 1.e. 
there is no stmistical signilicant difll:rcm.:c between the di!Tcrcnces b) and c). 
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4.1.4. Statistical Analysis of Pulse Rate 
PU LSE RATE (beats/min) 









Initial Reading Final Reading 
MEANS 
• midazolam 
Figure 10. Means of Pulse Rate for midazolam and non-midazolam cohorts 
Tab! 11 P 1 R t e u se a e summary o means f or nu azo am_an ± SE£ 'd d non-m1 azo am co o h rt 'd 
Initial Reading Final Reading Mean decrease sig. 
(PR1) (PR2) (PR1-PR2) (p) 
Midazolam (n = 49) 98.1 ±2.7 96.4 ± 3.1 1.7 ± 1.7 0.338 
no midazolam (n = 47) 88.1 ± 2.2 86.9 ± 2.2 1.1 ± 0.8 14 0.173 
Error bar =± SE (Standard Error) of the mean 
The mean decrease in pulse rate (beats/min) for the midazolam cohmt is 1.7 ± 1.7 after 
midazolam administered. Whereas, the mean decrease in pulse rate for the non-
midazolam cohort is 1.1 ± 0. 814. When comparing the statistical differences between 
these means there is no statistical significant difference between the mean PR decrease 
for the midazolam cohmt to the mean PR decrease for the non-midazolam cohmt. 
a) When comparing the significant difference between the initial Pulse Rate (PR) for 
both midazolam and non-midazolam cohorts (not shown in table format); p = 0.006 (as 
calculated by the SPSS Levene's Test for equality of variances). When p < 0.05 there is 
a statistical significant difference between the groups. In this case there is a significant 
difference between the initial PR readings for midazolam and initial PR for non-
midazolam cohorts. 
b) When comparing the significant difference between the initial and final PR reading 
for the midazolam cohorts; p = 0.338 when p > 0.05 there is no statistical significant 
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difference bct\vccn the groups. In this case there is no statistical signiJkunt diffcn:ncc 
between the initial reading (PR I) and tina\ reading (PR2) for the midazolam cohorts. 
c) When comparing the signiticant dilli::rcncc between the initial and Jinal PR reading 
for the non-midazolam cohort: p == 0.173 v.'hen p > 0.05 there is no statistical di!Tercncc 
between the groups. In this case there is no statistical signilicant difference between the 
initial reading (PR I) and !ina\ reading (PR2) forth\.' non-miduzolam cohorts. 
d) When comparing the statistical significant di!Tcrence between the final PR reading 
for the rnidazolam and non-midaznlam cohorts; p = 0.014 when p < 0.05 there is a 
signilicant dif!Crenee between the two groups. Therefore, there is a significant (p < 
0.05) diiTcrent:e between the final PR reading for the midazolam and ncm-midazolam 
cohorts. 
c) When companng the JillCrcnccs li.1r I'R between midazolam and non-midazolam 
cohorts: p = 0.939 when p > 0.05 there is no statistical signilicuncc bct\vecn the initial 
and final PR reading between the midazolam and non-midazolam cohorts. i.e. there is 
no statistical signilicant diJTercncc bchvecn the Jiffercnccs h) and c). 
41 
4.2. Analysis of Gender & Midazolam/Non-midazolam 
4.2.1. Statistical analysis of gender vs. systolic blood prcssu•·e 











Figure 11. Means of Blood Pressure (SBP) for males and females 









+M = mtdazolam 
-M = no midazolam 
I = initial reading 
F = fi nal reading 
a) Ini tial SBP 
Reading 
+M & -M 
+M = 122.7 
SE ±3.44 





p = 0.514 








p = 0.346 
no significance 
p = significance value 
SE± = Standard error mean 
M = males 
F = females 
b) Difference c) Difference d) Final SBP e) Statistical 
between between Reading Difference 
Initial & Final Initial & Final +M&-M between b) & c) 
SBP reading SBP readiJlg 
+M -M 
l = 122.7 1 = 126.5 +M = IJ 5.5 
SE± 3.44 SE± 4.67 SE ±3.56 
F = l15.5 F = 125.8 -M =125 
SE±3.56 SE±4.32 SE ±4.32 p = 0.079 
Mean decrease Mean decrease Mean no s ignificance 
7.2 ±3.28 0.72 ±3.28 difference 
p = 0.035 p = 0.709 10.3 ±5.83 
yes significant no signjficance p = 0.083 
no significance 
I = 123.3 I = 133.6 +M = 12 1.8 
SE± 8.1 5 SE± 6.52 SE±8.33 
F = 12 1.8 F = 130.5 -M =130.5 
SE ±8.33 SE±5.85 SE ±5.85 p = 0.798 
Mean decrease Mean decrease Mean no significance 
1.5 ±2.7 3. 1 ±1.23 difference 
p = 0.579 p = 0.018 10.3 ±5.83 
no significance yes s ignificant p = 0.393 
no significance 
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4.2.2. Statistical analysis of gender vs. oxygen saturation 
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Figure 12. Means of Oxygen Saturation for males and females 









+M = midazolam 
-M = no midazolam 
1 = initial reading 
F = fmal reading 
a) Initial Pa02 
Reading 
+M &-M 





1.74 ± 1.18 







0.2 16 ±1.31 
p = 0.870 
no significance 
p = significance value 
SE± = Standard error mean 
M = males 
F = females 
b) Difference c) Difference d) Final Pa02 e) Statistical 
between between Reading Difference 
Initial & Final lnitial & Final +M&-M between b) & c) 
Pa02 reading Pa02 reading 
+M -M 
I = 95.1 I = 96.9 +M =97 
SE ± 0.789 SE± 0.661 SE±0.666 
F = 97 F = 98.6 -M =98.6 
SE ±0.665 SE±0.269 SE ±0.269 p = 0.343 
Mean increase Mean increase Mean di fference no significance 
1.88 ±3.71 1.72 ±0.5 16 1.58 ±0.939 
p = 0.006 p = 0.006 p = 0.033 
yes s ignificant yes s ignificant yes sign ificant 
I = 95.7 l = 95.5 +M =97.5 
SE ± 1.33 SE ± 0.653 SE±0.955 
F = 97.5 F= 98.7 -M =98.7 
SE±0.955 SE±0.202 SE ±0.202 p = 0.798 
Mean increase Mean increase Mean difference no signjficance 
1.8 ±0.579 3.24 ±0.625 1.22 ±0.977 
p = 0.008 p = 0.000 p = 0.343 
yes significant yes significant no significance 
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4.2.3. Statistical analysis of gender vs. respiration rate 










Figure 13. Means of Respiration Rate for males and females 
Table 14. Respiration Rate summary of means and ±SE for gender 
Gender vs. a) In itial RR 
Respiration Reading 








p = 0.01 8 
)'es significant 
+M =24.4 
SE ±2. 14 
-M = 19. 1 
FEMALES SE ±0.608 
n=44 Mean 
difference 
6.29 ± 1.74 
p = 0.012 
ly_es sionificant 
+M = m1dazolarn 
-M =no midazolam 
I = initial reading 
F = fina l reading 
p = significance value 
SE± = Standard error mean 
M = males 
F = females 
b) Difference 
between 
Initial & Final 
RR reading 
+M 
I = 23.1 
SE ± 1.09 




p = 0.007 
)'es s ignificant 
I = 25.4 
SE ± 2. 14 




p = 0.353 
no s ignificance 
c) Di fference d) F inal RR e) Statistical 
between Reading Difference 
Initial & F inal +M& -M between b) & c) 
RR reading 
-M 
I = 19.9 +M =20.4 
SE± 0.766 SE±0.963 
F = 19.4 -M =19.4 
SE ±0.755 SE±0.755 p = 0.479 
Mean decrease Mean difference no significance 
0.444 ±0.304 0.997 ±1.22 
p = 0.163 p= 0.41 9 
no significance no significance 
I = 19.1 +M =23.3 
SE± 0.608 SE ±3.09 
F = 18.7 -M =18.7 
SE ±0.5 18 SE ±0.518 p = 0.439 
Mean decrease Mean difference no significance 
0.41 5 ±0.208 4.57 ±2.32 
p = 0.056 p = 0.165 
no significance no signi ficance 
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4.2.4. Statistical analysis of gender vs. pulse rate 











Figure 14. Means of Pulse Rate for males andfemales 
a e u se ate summary o T bl 15 P 1 R f means an ± or_g_en d SE fl d er 
Gender vs. a) Initial PR 
Pulse Rate Reading 




MALES SE ±3.88 
n=52 Mean difference 
16.7 ±5.03 






n=44 Mean difference 
3.46 ±4.92 
p = 0.486 
no significance 
+M = nudazolam 
-M = no midazolam 
I = initial reading 
F = final reading 
p = significance value 
SE± = Standard error mean 
M = males 
F = females 
b) Difference 
between 
Initial & Final 
PR reading 
+M 
1 = 103.8 
SE ± 3.03 




p = 0.218 
no significance 
I = 85.2 
SE ± 4.28 




p = 0.938 
no s ignificance 
c) Difference d) -Final PR e) Statistical 
between Reading Difference 
Initial & Final +M&-M between b) & c) 
PR reading 
-M 
1= 87.2 · +M =20.4 
SE ± 3.89 SE±0.963 
F = 85.3 -M =19.4 p = 0.952 
SE±3.79 SE ±0.755 
Mean decrease Mean difference no significance 
1.88 ±1.21 0.997'± 1.22 
p = 0.136 p = 0.007 
no significance yes significant 
I = 88.6 +M =20.4 
SE ± 2.8 SE ±0.963 
F = 88.0 -M =19.4 p = 0.847 
SE ±2.65 SE ±0.755 
Mean decrease Mean difference no sign ificance 
0.655 ± 1.09 0.997±1.22 
p = 0.554 p = 0.630 
no significance no significance 
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4.3. Analysis of Age & Midazolam/Non-midazolam 
4.3.1. Statistical analysis of age vs. systolic blood pressure 

















• initial SSP 
0 f inal SSP 
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Figure 15. Means of Systolic Blood Pressure for age categories 
Table 16. Systolic Blood Pressure summary of means and ±SE for age categories 
Age vs. 
Systolic a) Initial SBP 
Blood Reading 
Pressure +M &-M 
(SBP) 
+M = 121. 1 
SE ±4.63 
-M = 120.8 
<35yrs SE ±4.23 
n=40 Mean difference 
0.248 ±6.5 





>35yrs SE ±6.27 
n=54 Mean difference 
I 0.65 ±8.46 
p = 0.2 14 
no significance 
+M = m1dazolam 
-M = no midazolam 
I = in itial reading 
F = fi nal reading 
p = significance value 
SE± = Standard error mean 
b) Difference 
between 




SE ± 4.63 




p = 0.022 
yes s ignificant 
I = 125.9 
SE± 5.28 




p = 0.218 
no significance 
c) Difference 
between d) Final SBP e) Statistical 
Initial & Final Reading Difference 
SBP reading +M&-M between b) & c) 
-M 
I = 120.9 +M = I 14.9 
SE ± 4.23 SE±4.06 
F = 118 -M = 118 
SE ±4.05 SE ±4.06 
Mean decrease Me,an difference p = 0.253 
2.88 ±1.06 3.09 ±5.88 
p = 0.0 15 p = 0.603 no sign ificance 
yes significant no significance 
I = 136.5 +M = 120.4 
SE± 6.27 SE ±6.08 
F = 134.7 -M = 134.8 
SE ±5.48 SE ±5.48 
Mean decrease Mean difference p = 0.194 
1.8 ± 1.22 14.3 ±8.19 
p = 0.151 p = 0.086 no significance 
no significance no significance 
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Figure 16. Means of Oxygen Saturation/or age categories 
T bl 17 0 a e xygen s aturatwn summary o f d SE fl means an ± or age categones 
Age vs. 
a) Initial Pa02 Oxygen Reading Saturation 
+M &-M (Pa0 2) 
+M =96.2 
SE±0.83 1 
-M =98. 1 
<35 yrs SE ±0.358 
n=40 Mean difference 
1.88 ±0.036 
p = 0.046 
yes significant 
+M =94.5 
SE ± l.ll 
-M =94.9 
>35 yrs SE±0.642 Mean difference 
n=54 0.400 ± 1.22 
p = 0.745 
no s ignificance 
+M = midazolam 
-M = no midazolam 
I = initial reading 
F = final reading 
p =significance value 
SE± = Standard error mean 
b) Difference 
between 
Initial & Final 
Pa02 reading 
+M 
I = 96.2 
SE± 0.831 




p = 0.009 
yes signi fi cant 
I =94.5 
SE ± 1.11 




p = 0.012 
ves s ionificant 
c) Difference 
between d) Final Pa02 e) Statistical 
Initial & F inal Reading Difference 
Pa02 reading +M & -M between b) & c) 
-M 
I = 98.1 +M =97.4 
SE± 0.358 SE ±0.6 15 
F = 99. 1 -M =99. 1 
SE ±0.168 SE ±0.168 
Mean increase Mean difference p = 0.170 
1.06 ±0.290 1.73 ±0.732 
p = 0.002 p = 0.024 no significance 
yes significant yes significant 
I = 98.1 +M =96.8 
SE ± 0.358 SE±0.936 
F = 99.1 -M =98.5 
SE ±0.168 SE ±0.223 
Mean increase Mean difference p = 0.042 
3.56 ±0.290 1.67 ±0.963 
p = 0.000 p = 0.094 yes sign ificant 
ves significant no significance 
47 
4.3.3. Statistical analysis of age vs. respiration rate 










Figure 17. Means of Respiration Rate for age categories 
T bl 18 R f R t a e esp1ra 1011 a e summary o f means an d±SE£ te or age ca :gen es 
Age vs. a) Initial RR 
Respiration Reading 
Rate (RR) +M & -M 
+M =24.4 
SE ± 1.40 
-M =19.5 
SE ±0.758 
<35 yrs Mean 
n=40 difference 
4.86 ± 1.59 
p = 0.005 
ves s ignificant 
+M=23 
SE ± 1.49 
-M =19.3 
SE ±0.61 6 





+M = m1dazolam 
-M = no midazolam 
I = initial reading 
F = final reading 
X. = mean 
p =significance value 
SE± = Standard eiTor mean 
b) Difference 
between 
Initial & Final 
RR reading 
+M 
I = 24.4 
SE ± 1.40 
F = 21.8 
SE ± 1.00 
Mean decrease 
2.6 ±1.27 
p = 0.052 
no significance 
I = 23. 1 
SE ± 1.49 
F = 2 1.1 
SE ±2.16 
Mean decrease 
1.95 ± 1.34 
p = 0.158 
no sign ificance 
c) Difference 
between d) Final RR e) Statistical 
Initial & Final Reading Difference 
RRreading +M& -M between b) & c) 
-M 
I = 19.5 +M =2 1.7 
SE ± 0.758 SE ± 1.00 
F = 19.2 -M = J9.2 
SE ±0.768 SE ±0.768 
Mean decrease Mean difference p = 0.671 0.352 ±0.308 2.61 ± 1.27 
p = 0.269 p = 0.047 no significance 
no significance yes significant 
I = 19.3 +M =21.1 
SE ± 0.616 SE ±2. 16 
F = 18.9 -M =18.8 
SE ±0.522 SE ±0.522 
Mean decrease Mean difference 
0.466 ±0.207 2.26 ±2.22 p = 0.1 77 
p = 0.032 p = 0.320 no significance 
yes s ignificance no significance 
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Figure I 8. Means of Pulse Rate for age categories 
Table 19. Pulse Rate summary of means and ±SE for age categories 
Age vs. 
a) Initial PR P ulse Reading Rate 




<35 yrs SE ±2.97 
n=40 Mean difference 
10.9 ±5.5 
p = 0.054 
no significance 
+M =92.7 
SE ±3.0 1 
-M =85.7 
>35 yrs SE±3.02 
n=54 Mean difference 
7.05 ±4.32 
p = 0.109 
no significance 
+M = m1dazolam 
-M = no midazolam 
I = initial reading 
F = final reading 
p = significance value 
SE± = Standard error mean 
b) Difference 
between 
Initial & Final 
PR reading 
+M 
[ = 103.3 
SE± 4.62 
F = 29.6 
SE±4.67 
Mean decrease 
3.65 ± 1.72 
p = 0.045 
xes s ignificant 
I = 92.7 
SE± 3.0 1 




p = 0.684 
no significance 
c) Difference 
between d) Final PR e) Statistical 
Initial & Final Reading Difference 
PR reading +M&-M between b) & c) 
-M 
1 = 92.3 +M =99.6 
SE ± 2.97 SE ±4.67 
F = 89.6 -M =89.6 
SE ±3.30 SE ±3.30 
. 
Mean decrease Mean difference p = 0.814 2.64 ±1.16 9.96 ±5.7 
p = 0.037 p =0.090 no significance 
xes significant no significance 
I = 85.7 +M =93.9 
SE± 3.03 SE ±4.54 
F = 85.4 -M =85.4 
SE ±2.84 SE ±2.84 
Mean decrease Mean difference p = 0.623 0.266 ±1.07 8.48±5.15 
p = 0.806 p = 0.106 no significance 
no significance no significance 
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4.4. Analysis of Head Injury & Midazolam/Non-midazolam 
4.4.1. Statistical a nalysis of head inj ury vs. systolic blood pressure 
- - - ----- - - - --






a. 60 ~ 40 
20 
· 0 
• in itial SSP 
0 final SBP 
Figure 19. Means ofSystolic Blood Pressure for head injuries 
Table 20. Systolic Blood Pressure summary of means and ±SE for head injuries 
Head Injury vs. a) Initial SBP 
Systolic Blood Reading 
Pressure (SBP) +M &-M 
+M =125.2 
SE ±5. 14 
-M=13 1 








-M = 130 
MODERATE/ SE±10.7 
SEVERE Mean 
TB I d ifference 
n=40 8.57 ±9.96 
p = 0.395 
no significance 
+M = mtdazolam 
-M = no midazolam 
I = init ial reading 
F =final reading 
p =significance value 
SE± = Standard error mean 
b) Difference 
between 
Initia l & Final 
SBP read ing 
+M 
I = 125.2 
SE± 5. 14 
F= 118.9 
SE ±4.9 1 
Mean decrease 
6.2 1 ±3.45 
p = 0.089 
no significance 
I = 121.4 
SE± 4.54 




p = 0.148 
no signi ficance 
Mild TBI = mild traumatic brain injury 
MIS TBI =moderate/severe traumatic brain injury 
c) Difference d) Final SBP e) S~atistical 
between Reading Difference 
Initial & Final +M&-M between b) & 
SBP reading c) 
-M 
]= 131.1 +M = 1 18.9 
SE ± 4.86 SE ±4.9 1 
F = 128.5 -M = 128.5 
SE±4.39 SE ±4.39 p = 0.099 
Mean decrease Mean no significance 
2.67 ± 1.01 difference 
p = 0.01 2 9.5 ±7.07 
xes significant p = 0.185 
no significance 
I = 130 +M = 116.4 
SE± 10.7 SE ±4.91 
F= 129.6 -M = 129.6 
SE ±9.41 SE±9.41 p = 0.308 
Mean decrease Mean no significance 
0.4 ±0.259 difference 
p = 0.801 13.2 ± 10.1 
no significance p = 0.1 99 
no significance 
50 
4.4.2. Statistical analysis of head inj ury vs. oxygen saturation 
Head Injury v s. Oxygen Saturation (Pa02) 
100 
98 
~ 0 96 
• initial PaJ N 
0 
o final Pa02 CIS 94 Q. 
92 
90 
Figure 20. Means of Oxygen Saturation for head injuries 
Table 2 1. Oxygen Saturation summary of means and ±SE for head injuries 









+M = mtdazolam 
-M = no midazolam 
I = initial reading 
F = fillal reading 

















p = 0.818 
no significance 
p = significance value 
SE± = Standard error mean 
b) Difference 
between 
Initial & Final 
Pa02 read ing 
+M 
I = 97.8 
SE ± 0.394 




p = 0.511 
not significant 
I = 93.8 
SE ± 0.978 
F = 96.4 
SE ±0.7 13 
Mean increase 
2.66 ±0.501 
p = 0.000 
ves significant 
Mild TBI = mild traumatic brain injury 
MIS TBI = moderate/severe traumatic brain injury 
c) Difference 
between 
Initial & Final 
Pa02 reading 
-M 
I = 96.5 
SE ± 0 . .469 
F = 98.7 
SE±O.l76 
Mean increase 
2. 19 ±0.447 
p = 0.000 
~es significant 
I = 94.2 
SE ± 1.36 




p = 0.004 
lves sifmificant 
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d) Final Pa02 e) Statistical 
Reading Difference 




SE±O. I76 p = 0.432 
Mean difference no sign ificance 
0.36 1 ±0.602 
p = 0.551 
no significance 
+M =96.4 
SE ±0.7 14 
-M =98.6 
SE ±0.40 p = 0.012 
Mean difference ~es significant 
2. 17 ± 1.28 
p = 0.095 
no significance 
4.4.3. Statistical analysis of head injury vs. respiration rate 














• initial RR 
o final RR 
Figure 21. Means of Respiration Rate for head injuries 
Table 22. Respiration Rate summary of means and ±SE for head injmies 









+M = mtdazolam 
-M =no midazolam 
I = initial reading 
F = final reading 



















p = 0.001 
yes significant 
p = significance value 
SE± = Standard error mean 
b) Difference 
between 
Initial & Final 
RR reading 
+M 
I = 22.6 
SE ± 1.31 
F = 20.9 
SE ± l.39 
Mean decrease 
1.63 ±0.922 
p = 0.094 
no significance 
I = 24.6 
SE ± 1.39 
F = 21.5 
SE ± 1.68 
Mean decrease 
3. 1 ± 1.41 
p = 0.035 
yes s ignificant 
Mild TBI = mild traumatic brain injury 
M/S TBI = moderate/severe traumatic brain injury 
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c) Difference d) Final RR e) Statistical 
between · Reading Difference 
Initial & Final +M& -M between b) & c) 
RR read ing 
-M 
I = 19.5 +M =20.9 
SE ± 0.570 SE ± 1.39 
F= 19 -M = 19 
SE±0.506 SE ±0.505 p = 0.412 
Mean decrease Mean difference no significance 
0.486 ±0.211 1.86 ± 1.48 
p = 0.027 p b 0.221 
yes s ignificant no significance 
I = 18.8 +M =21.5 
SE± 0.742 SE ± 1.68 
F = 18.6 -M = 18.6 
SE±0.791 SE ±0.792 p = 0.611 
Mean decrease Mean difference no significance 
0.20 ±0.20 2.93 ±2.97 
p = 0.343 p = 0.330 
no significance no significance 
4.4.4. Statistical analysis of head injury vs. pulse rate 
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Figure 22. Means of Pulse Rate for head injuries 
• initial PR 
D final PR 
T bl 23 P 1 R t a e u se a e sununary o f means an d ±SE £ d" or 1ea mJunes 
Head Injury vs. a) Initial PR Reading Pulse Rate (PR) 





n=56 Mean difference 
6.98 ±5.02 
p = 0.1 77 
no significance 






n=40 10.8 ±7.25 
p = 0.144 
no significance 
+M = mtdazolam 
-M = no midazolam 
I = initial reading 
F = final reading 
p = significance value 
SE± = Standard etTor mean 
b) Difference 
between 
Initial & Final 
PR reading 
+M 
I = 94.7 
SE ± 4.54 
F = 92.7 
SE ±5.1 2 
Mean decrease 
2.0 ± 1.5 
p = 0.200 
no significance 
I = 100.3 
SE± 3.44 




p = 0.589 
no significance 
Mild TBI = mild traumatic brain injury 
MIS TBI = moderate/severe traumatic brain injury 
c) Difference 
e) Statistical between d) Final PR Difference Initial & Final Reading 
PR reading +M&-M between b) & 
-M c) 
I = 87.7 +M =92.6 SE±5.12 SE± 2. 14 
-M =8).7 F = 85.7 
SE±2.07 SE±2.07 
Mean decrease Mean 
1.94 ±0.909 difference p = 0.978 
p = 0.039 6.92 ±5.52 no significance 
yes significant p = 0.222 
no significance 
I = 89.5 +M =98.8 
SE± 7.22 SE ±3.94 
-M =91.4 F = 9 1.4 SE±6.84 SE ±6.84 
Mean decrease Mean 
1.9 ± 1.55 difference p = 0.684 
p = 0.252 7.46 ±7.88 no significance 
no significance p = 0.349 
no significance 
53 









Mild TBI vs SBP 
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Figure 23. Means ofSystolic Blood Pressure for Mild TBI 
T bl 24 S t 1' Bl d P a e ys 0 IC 00 ressure summary o f means an d ±SE fi M'ld TBI or 1 
Initial vs. Initial vs. Final Initial SB P Final SBP 
Final SBP reading reading 
SBP no midazolam +M&-M +M&-M 
Midazolam (n= 37) 
(n= 19) 
1 = 125.2 1=131.1 I =129. 1 F =125.2 
SE ±5. 14 SE ±4.86 SE ±3.64 SE ±~.38 
F =ll 8.9 F =128.5 p = 0.20 1 p = 0.078 
SE ±4.91 SE ±4.39 no significance no significance 
p = 0.044 p = 0.006 
yes significant yes significant 
Mild TBI vs Oxygen Saturation 
100 ,-------------.., 
99 -+--~~-=----,= 






• rtidazolam j 






3.87 ± 1.35 
p = 0.168 
no significance 
Figure 24. Means of Oxygen Saturation for Mild TBI 
Table 25. Oxygen Saturation summary of means and ±SE for Mild TBI 
Initial vs. Initial vs. Final Initial Pa02 Final Pa02 Statistical difference 
Final Pa02 reading reading between the 
Pa02 no midazolam +M&-M +M& -M differences 
midazolam (n= 37) for +M& -M 
(n= 19) 
I =97.8 I =96.5 I =96.9 F =98.6 Mean difference 
SE ±0.394 SE ±0.469 SE ±0.345 SE±0.283 1.64 ±0.423 
F =98.4 F =98.7 p = 0.023 p = 0.327 p = 0.054 
SE ±0.773 SE ±O.l76 yes signjficant no signi ficance no significance 
p = 0.255 p = 0.000 




















Figure 25. Means of Respiration Rate for Mild TBI 
Table 26. Respiration Rate summary of means and ±SE for Mild TBI 
Initial vs. Initial vs. Final Initial RR Final RR Statistical difference 
Final RR reading reading between the 
RR no midazolam +M& -M +M& -M differences 
Midazolam (n= 37) for +M& -M 
(n= 19) 
I =22.6 I = 19.6 l =20.6 F = 19.7 Mean difference 
SE ±1.3 1 SE ±0.570 SE±0.608 SE ±0.583 0.875 ±0.344 
F =20.9 F = l9 p = 0.023 p = 0.110 p = 0.119 
SE ±1.39 SE±0.505 yes significant no significance no significance 
p = 0.047 p = 0.013 
yes s ignificant yes significant 
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Figure 26. Means of Pulse Rate for Mild TBI 
T bl 27 P 1 R t a e use a e summary o f means an d SE f, M"ld TBI ± or 1 
In itial vs. Initial vs. Final Initial PR Final PR Statistical di fference 
Final PR reading reading between the 
PR no midazolam +M& -M +M&-M differences 
midazolam (n= 37) for +M& -M 
(n= 19) 
I =94.7 I =87.7 I =20.6 F = l9.7 Mean difference 
SE ±4.55 SE±2.l4 SE±0.608 SE±0.583 1.96 ±0.780 
F =92.7 F =85.7 p = 0.088 p = 0.111 p = 0.488 
SE ±5. 12 SE ±2.07 no significance no significance no significance 
p = 0.100 p = 0.013 
no yes significant 
significance 
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Figure 27. Means of Systolic Blood Pressure for Moderate TBI 
T bl 28 S t 1· Bl d P a e ,ys o 1c 00 ressure summary o f means an or 0 d ±SE £ M d TBI 
Initial vs. Initial vs. Final Initia l SBP Final SBP Statistical difference 
Final SB P reading reading between the 
SBP no m.idazolam +M&-M +M &-M differences 
midazolam (n= 9) for+M & -M 
(n= 16) 
Moderate I =127.4 I = 131.1 I =128.7 F =125.3 Mean difference 
TBI SE±6.69 SE ± I 1.8 SE ±5.92 SE±6.29 0 3.4 ±3.6 
vs. F = 122.2 F =130.8 p = 0.394 p = 0.258 p = 0.202 
SBP SE ±8.05 SE±10.4 no significance no significance no significance 
p = 0.183 p = 0.450 
no no significance 
significance 










Figure 28. Means of Oxygen Saturation for Moderate TBI 
T bl 29 0 a e xygen s aturat10n summary o f means an d SE £ M d ± or o erate TBI 
Initial vs. Initial vs. Final Initial Pa02 Final Pa02 Statistical difference 
Final Pa0 2 reading reading between the 
Pa02 no midazolam +M&-M +M& -M differences 
midazolam (n= 9) for +M &-M 
(n= 16) 
Moderate I =92.8 I =94.1 I =93.3 F =97.2 Mean difference 
TBI SE±l.46 SE ±1.5 1 SE ± 1.07 SE ±0.702 3.92 ±0.658 
vs. F =96.4 F =98.5 p = 0.272 p = 0.037 p = 0.296 
Pa02 SE ±1.03 SE ±0.444 no significance yes significant no significance 
p = 0.000 p = 0.004 
yes significant yes significant 
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Initial ReadiJJ& Final ReaditJ& 
Figure 29. Means of Respiration Rate for Moderate TBI 









Initial vs. Initial vs. Final Initial RR Final RR Statistical difference 
Final RR reading reading between the 
RR no midazolam +M& -M +M& -M differences 
midazolam (n= 9) for+M &-M 
(n= 16) 
I =19.1 I =22.8 F =20.3 Mean difference 
I =24.9 SE ±1.7 SE±l.24 SE±0.978 2.48 ± 1.19 
SE ±1.7 F = 18.8 p = 0.003 p = 0.089 p = 0.035 
F =21.2 SE ± 1.43 yes significant no significance yes significant 
SE ± 1.43 p =0.173 
p = 0.028 no significance 
yes significant 
Moderate TBI vs Pulse Rate 
110 .---------------------~---. 
105 ~---~ 
• rridazolam l 
c no l[idazo~amJ 
85 
80 
Figure 30. Means of Pulse Rate for Moderate TBI 
Table 31. Pulse Rate swnmary of means and ±SE for Moderate TBI 
Initial vs. Initial vs. Final Initial PR Final PR Statistical difference 
Final PR reading reading between tbe 
PR no midazolam +M&-M +M& -M differences 
Midazolam (n= 9) for +M&-M 
(n= 16) 
I =99.2 I =89.6 l =95.8 F =94.3 Mean difference 
SE ±4.97 SE±8.07 SE ±4.3 1 SE±4.80 1.48 ±2.88 
F =95 .7 F =91.7 p = 0.165 p = 0.346 p = 0.124 
SE ±6.31 SE ±7.63 no significance no significance no significance 
p = 0.219 p=0.127 
no no significance 
sign ificance 
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4. 7. Severe TBI Results 
Severe TBI vs Systolic Blood Pressure 













Figure 31. Means of Systolic Blood Pressure for Severe TBI 
Table 32 S r Bl d P ;ysto 1c 00 ressure summary o f d ±SE £ S means an or eTBI ever 
Midazolam (n= l4) Initial Final Statistical difference 
No midazolam (n= l) SBP SBP between Initial vs. Final 
Severe TB I mean = 11 5 mean = 110 
vs. SE = ± 5.36 SE =± 4.53 
SBP 








Initial Reading Final Reading 
Means 
SBP 
p = 0.098 
no significance 
Figure 32. Means of Oxygen Saturation for Severe TBI 
Tabl 33 0 e xygen s aturatwn summary o f means an ± or d SE£ S evere 
Midazolam (n=14) Initial Final Statistical difference 
TBI 
No midazolam(n= l) Pa02 Pa02 between In itial vs. Final 
Pa02 
Severe TBI mean = 94.8 mean = 96.6 p = 0.002 
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Figure 33. Means of Respiration Rate for Severe TBI 
a e espua wn a e summary o T bl 34 R f R t f means an d ±SE fl S or evere TBI 
Midazolam (n=l4) Initial Final 
No midazolam (n=l) RR RR 
Severe TBI mean= 23.7 mean = 21.5 
vs. SE =± 2.25 SE=±3.08 
RR 
Severe TBI vs Pulse Rate 
108,------------=~~----~--
106 +--- -~ 
100 
98 
Initial Reading Final Reading 
Statistical difference 
between Initial vs. Final 
RR 




Figure 34. Means of Pulse Rate for Severe TBI 
Table 35. Pulse Rate summary of means and ±SE for Severe TBI 
Midazolam (n= 14) Initial Final Statistical difference 
No midazolam (n= l) RR RR between Initial vs. Final 
RR 
Severe TBI mean = 100.6 mean = 101 p = 0.385 




Millazohtrn/Non midawlam analysis 
The analysis of the systolic blood pressure (SBP) in relation to midazolam and non· 
midazolam cohorts shmnxl a statistical signilicancc bct\'iccn initial and final readings 
for cnch cohort (sec table 9). The lower initial SBP readings for the midazoiam cohort 
may be a consequence nf the mulliph: injuries sustained by the patients. Such i11jurit:s to 
the hl:ad imply greater blood loss. therefore rcsulling in lo\',:cr initial SBP readings s5• 
The mean decrease for the midazolam cohort was greater than 5 mmllg which was not 
considered clinically significant as patients were not in danger of reaching a 
hypotensive state 72 . There was also a significant diiTcrcncc between the final readings 
comparing both midazolarn and non·midazolam cohorts. The tina[ reading for the 
midazolam was not as high as the non·midaznlam cohort (sec table 9). llowevcr the 
mean final reading was consid~.:red safe and was not imlicativc of hypotension. 
A statistical significance was also noted bet\vecn the initial and linn\ readings for 
oxygen saturation in the midazolam and non·midazolam cohorts (sec table 10). It is 
important to note that all patients in this study received oxygen supplementation during 
treatment. This explains the increase in final oxygen saturation readings for both the 
midazolam and nmHllidazolam cohorts. There is a stutistical significance bc:t\vccn the 
final Pa02 rcadmg between midazolam and non-midazolam cohorts. Midazolam·s !ina! 
PaO~ readings increased to 97% compared to a 99% PaO~ increase for the non· 
midazolam colwrt. Again this may he due to the severity of injuries sustained by the 
midazolam study ptlpulation. 
Tbl! analysis of respiration and pulse rate in relation to midazolam and nmHnidazolam 
cohorts revealed a signilicant di!Tcrcncc hcl\vccn initial respiration and pulse rate 
reading for the mida;.~olam cohort (tables 11 & 12). Patients treated with midazolam 
expressed higher initial respiration and pulse rate readings compared to no!Hllidazolam 
patients. This may be Juc tu the fact that patients treated with midazolam displayed 
um:ontro\lablc or aggressive behaviours which directly correlate to increased 
physiological breathing and ht:art rate patterns. Although there \Vas a noted statistical 
di!Tert:nce between initial respiration and pulse rate readings for the midazolam cohort 
this was of no clinical signilicance. 
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Gender category 
In relation to the companson of initial and linal readings, midazolam and non· 
midazolum groups for males, it \vas interesting to note that there was a significant drop 
in SBP (sec table 13. figure 10). This translates to a signilicant drop in oxygen 
saturation when comparing these same groups; IHl\\evcr this is not or diniL'ai 
importance ami probably relates to the naturl.! of the injuries of thi.! group. It must bL• 
borne in mind th<lt the patients selected to receive midazolam were not randomly 
selected. but were allocated the drug on the basis of their antisocial or unL'ontrolbhlc 
behaviour. This ClHild ac~.:ount for the dilli:renccs noted between initial n:adings of both 
midazolam and nmHniJazolam group in respect of puls-e and rL'spimtion rate. 
Dirt~renccs between the initial readings of these groups in n:spcct ofoxygL'll satumtion 
and blood pressun: were also noted. but Wl.!rc nPt or stutisti~:al signi licancc. 
The analysis of oxygen saturation on the basis of gender 1\.'\'ca\cd no signiticant 
dift~tcnccs between initial and tina\ rcadin~s. in those patil..'nts given midazolam rdati,·e 
to those patients who did not receive midnml.1m for citlwr thl.! males or fcmaks. Yet the 
males displayed a signiticant drop in !ina\ reading under the irtluencc of mida;.olam 
(sec table 14). Discounting physiological dirt'erencl.!s. this rt.d1ccts tht: seriousness of the 
injuries of the male cohort. especially in rdntion to hc.:~d i11iurics. whkh mainly arosl.! as 
a conscqm::ncc of motor n:hich.: accidents. The m~~iority of maks in this study m.:rc 
aged between 25 to 35 years and were involved in motor vehicle accidents. wbill.! the 
majority of Ji:maks were agl..'d 66 years and o\dl..'r and sustained head injuries due to 
lUlls and direct trauma to L,~·~ head. This natural bias in the data could not he overcome 
due to the limitations nf complete patient care records. 
Age category 
The age vs. Systolic Blood Pressure category did not present statistical signillcanet: for 
the Jess than 35 year olds. In this category. patients treated with mitlazolam recorded 
14.3 mm Hg less than those not treutcd with midazolam. The under thirty lives showed 
a 6.2 mm Jig mean dccn.:asc for the mida1-olam patients compared to a 2.8 mm Jig in 
the non·midazolam group (sec tabll.! 17). 
A statistical signiticancc was noted in all hut three variables in relation to age vs. 
oxygen saturation. Patients 35 years and older recorded similar 111\!all oxygen saturation 
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midazolam cohnrt displayed a higher initial n:spiration rate than th~.: mild head injuries 
no-midazulam C\lhnrt the greater decn:asc in breathing rate after administration of 
mida...:{ll.un shm\cJ this to he of nn clinical signilicancc. 
l'<.~ticnts tr~:atl'd ''ith midawlum displa:-~.:J higher initial anJ final pulse rate reading 
than the nun-nmla;n\am cohnrt. This cotllJ he due th..: l~1..:t that tb1.• patients tn:ateJ \\'ith 
midan1lam an.: a sdcl'l gru11p displaying uncontrtl\\ablc or aggrcssi\'e hehaviours. When 
C\llllparing pulse rak bd\\een mida/llla!ll and nun-midamlam cohorts. a larger drop in 
pulse rate \\as nuted \\ ith the non-mida/_o\am cohort. 
.\lnLkr;l!~.· 1 kud injurv 
A statisti..:all) signiticmlt mereo1se Ill 11Xygen saturmion \\as recorded for both 
midMolam and Twn-mid<JJ.nlam patient:-;. Statistical signiticanee was abo noted fm the 
mean tinai u:-..~go.:n :-.atur•ttiun n:adin); iS~.:e table ]0) hci\\O.:l'll the mida;:nlam and nnn-
midazulam p:1tienh: it duo.:s Tl\lt r~.·aeh 9K"o. It is important th;u o.':-gen s.:tturatiun 
re;H.Iin~s r~.·;Kh 'fk"u during la:dd triHIIl1<1. 1\tl\\f.!\l'f. patient:> \rL':lt..:d Juring this study all 
rceei\t:d n\~gen ·.uppknH:nt:ttinn and P\~gen saturatiun I'L'adings \\o.:re carefully 
maintained and 11\Pilil\lfi.!d. :\ 1JX" o tl\) gen saturaliPn reading docs THlt indio.:ute h~ pu:da 
ami is ofntllktrimental~.·fket to paticnts 1 ~>. (>IlL' ofthL' prnhlems in interprl'till); the data 
i .... the uncertain!~ nf \lhat phamT<tL'L·uticuls tor Ptha drugs) the p<~tienls h;L\1.' in their 
sy.~tcms. •mJ \l]ll.'th..:r the :H.illliJli..,tratillll 11f mid:lllll:illl I\ ill Ji.-;place these ag~.:nb from 
thL' tran .... ptlrt pn1tt:i1b 111 the bhl{llbtre:llll. pn1ducing multil';.u,:torial erti:ets. 
The larger drup in breathing rate lilT the !llida/.\llam Ctlllllrl eomparcd tn tlnly a I. 7 re~ps 
per minuto.: drup in the non-midal\ll:un su):!gt.:sts midah1lmn patio.:nt:-. Jisplayl'd l~tster 
breathing jMlkm~ than the patient:-. lllltlrL'<LtL'd \\ith mid<J;:p\;un. :\g<~in this ma:- he du1.' 
111 e;tch p;t\IClll trL·all'd 11ith mida/11lam di:-.pb,1ing :tggrL'ssile ur lllll.:tltlJll.'ratile 
hdla\Hlllr:-. thcrdill'l' tho.:se p<itll'llls' ph~ ... iolugiea\ respon.~L':-- \\l'ft: increasL·d. Abtl. 
although till' mc,ll\ initi.d read in):.' \Ia:-- higher in midil!tllan\ patients than nun-mida;nlam 
patiL·nts \see tahk _\I). •dl patiL'llb tr~.·ated 11 ith lllidalllkilll did 1111t Ji:-,p\a~ irregul;1r 
hrt.:<tthing pal1L'Jil~. I be 1\ll'rall drop in re:-.piratioa r;tll' did no\ i'L'aL·h clini~.·;Ll dwll,!l'r 
le1L'I~ liu· indi1 idu;ds ·m ·II 
No statisti(.;a\ significam:c was found with systolic blood pn:ssun:: or pulse rate bl!twccn 
mid.:1zolam treated p<.tticnts and untrcaLt.:d patients. Jlnwcvcr the midazolam cohort 
displayed a \nW~:r s,;.stnlic blnoJ prcssun.: (sec tahh: 2~) for hoth the initial TCllding and 
tina\ n:aJings ''hen compmeJ tu <1 much higher systolic rcmling for the non-miJazo\am 
cohort. This is unusual <ts p:1tients n.:cci,·ing midazolam display aggrcsstvc 
charm:\l.:ristics that could inllm.•ncc incn .. '<t<>cd symptoms of hypuh:nsiun. 1\owcn:r, this 
cnu\J he i..!XplaincJ as patio.:nts treated with midazolmn suswincJ a slightly higher CJCS 
score. which suggl..'sts the more severe thL' h~.-·ad injury the greater th~.:: hloml loss 
. 'h . "' cxpcr!l.!llt:l'u y pal tents . 
Scn:n: I kaJ !njurit.'s 
lhl' mt.'an drop in s~ :-.tnli~ hloml prt.'S'>t:rt: for the st:vt:rcly ht:ad injurt:d patients is 5mm 
llg. Thl..' initial SBP reaJillg (s~e table ]3) was not consiJen:d high and in raet it is 
within th~ nnrmal ht.'ahhy range. The drop in SBP is th~.:n:forc not clinically signilieant 
to patil'nts. as tlwy "~re nnt hypott:nsiw x.'. 
A statisti~..:al signific:mce in thl: inncasc or (lXygen :-.aturation was lltlt~J. I [ll\\e\'l'T tht: 
increase is not clinically signiflt:illll c\·en tlwugh the tina! oxygen saturati\m docs not 
re.:1ch 'J7"-,. It is important to puint out tlwt the patients in the modt.'ratc ht:ad injury 
category h.:1W a 1\lO...:illl nf 'J7"·;) ox~gL'I1 saturation. thl' ~am..: as the s~:wrd~ bead injured 
patients. Tlw litl't tlwtthL· se\ercly h~:ud it~iurL·d patil'nts <tnd the nwderate ht.'aJ injun.:J 
patil'nts had :-.imil.:tr O\~):!L'!l :-.<~turatiun lc\cls \aliJates t:l.llllhining tlwso...: groups in thl.! 
SPSS study. 11 i~ al~o :-.upp,lrlillt' l'\ idL'llCL' th<~t thL' k·\ el uf \lX)gcn administration 
during tran~p(lr\atiun to hu~pital IS itppropri;t!L' lilT o.:;tdl ur tlll' .... (: patio...:nl ~.::atcguri..:s. It 
shuuld h..: hunK in mimi that :m:. pnl!.:ll\ial dh.·cts uf n.:duL·in~ {1.'\ygo.:n suturation by 
miJ;l/l.l!<ttll WuiJ hL' l'Ullll\(:r<ll'\l:d h~ thl' aJmini:-.tra\il.lll \lr{l:\~~L'n '·'I. 
1\u ditHcal :-.igniti•:alli.:L' \\as 110k'd \\ith r(:spiration rat..: nr puis(: rate in tilL' Sl'\·crdy 
head injun:d C11hnrt. The se\Cr(:ly head injur(:d p<ttiL·nts displayL·J slightly higher 
injured paticnts. )ll\(:I'L'Stingl~ th...:~ di~p\;•)Cd hml'r :-.~stnli~.: blood pr~ssurc and 
breathing rak redding-. than thL' nlo,krak h..:ad injunL'S. lhi~ nwy hc due to S\\1.dling 
impinging nnth..: canhu\a:-.cular mo.:dul!ar) co...:ntrl.'s in the brain)('. 
Comparing th~ analysis of th~ mild vs. mod~ratc/s~vcrc h~ud injurit:s in the Exc~.·l 
analyses slllm~d no t.listim:t Jifll:r~ncc hi • .'twccn the two cohorts. Both t\wsc cohorts 
displayed statistically ~;igni1icant dilkrcnc~s in oxygen saturation n.:mlings and a 
statistical signilicancl' found in syswlk blouJ pressure. r~spiration rate or pube rate in 
patients r~cciving mida;u\am relative tn untrcat~d patients. Alsn when comparing 
nllld~ratl' \·s. s1:wrc head injuries oxygen saturation \"aria hies stoud out and Doth cllhorts 
disp\ay~d statistical significance suggesting hypoxic acti\"ity is prcs~nt in tr~atcd 
pati~nts. 
6. Conclusion 
This stlldy has JcmonstrntcJ that mit!azol~un is a sati: ami ert~ctivc sedating agent used 
in the treatment nf aggressi\'e anti unctmtrollabk• patients who hiiVC sustilim:J a head 
lllJUry. The tlt1sage of mid;unlam used on patients in this study ntrid rnllll 5mg In 
25mg. Tht: patients \\ho received 25rng ot' miJawlam displayed similar physiological 
effects to those patients \\ho only recei\·ed 5mg of midazolam. Ultimately the \'ari~.·J 
dosage of mida1nla111 used to tre<tl aggressin: heaJ injureJ p<1ticnts Jues not eaus~.: an 
im:rease in either hypot~·n:-.inn or hypoxia. 
It is interesting to speculate what woukl happen to oxygen sawration rt:adings if no 
ux~ gen supplcmentatiun wa~; administert:d to patients Juring treatment with 
mid<u:olam'! \\'hat \\nuld oxygcn saturatinn levels be? It is our sp~·eul<ttion that oxygen 
saturation lc\els \\lll!]d in fact remain f<tirly low if no oxygen supplcmcntation ''as 
giH'B tn patients Juring mid~lzolam usc. lhen.:fore hypnxia in patient's udminisiered 
mida!ol<llll ,,-,1uld tx· anticir<tted ''I. 7:-_ 
lncrcases in respiration raiL' in patients tre.:tted with midawlam appear in the g~nder. age 
and hl.!ad injur) gruups. i\'lidawl.:un may lx.· more <11.!\i\'e on the respiratory C!.:"llii\!S of the 
brain sli.!lll fpuntine) than the cardiovas<.:ul.:tr lllL·dul!ary Ci.!lltr< ... -lh 
Ultimately this study fuund miJat.olarn treatmcm did in!lut.'llL'I.' d~.·,:rcasc in SBP. an 
incr :asl.! in pulse rail' and hew1 ratc ' 11 ~dong with lnwl.:"r oxygen saturatitlll lcvds. 
1\il\\e\'l'r. in this study thc \';triahles an; of no clinical signilicanct: ~'~- ·~~ 'l.1 and do not 
sug).!est h)pnxia t•r hyptl\cnsinn in patients. On the basis ufthis data and the anal~:-es 
carried out. thcrc \\L're no Jemon:-trahlc dell'tcrious dkcts of midazulam nn uxygcn 
saturatiilll or hlouJ prL·ssurc in head injured patients. This is supporting evidence that 
this is a comparati\cly sali: drug fur usc in the prehospital setting. 
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Appendix 2 
STJOHN AMBULANCE AUSTRALIA 
W.A. AMBULANCE SERVICE INC. 
HEAD TRAUMA: 
Clinical Practice Guideline 20 
September, 2004 
Assume cervical injury until proved otherwise refer to CPG 31 (Indications for 
Spinal Precautions). 
Specific information needed: 
History: 
• Mechanism of injury. 
• Estimate of force involved, potential for concealed injury. 
• Change in level of consciousness since injury. 
• Amnesia for events prior to and/or following trauma. 
• With motorcycle, bicycle and industrial accidents, was a helmet 
worn? 
• How does patient feel? Movement, sensation, numbness, tingling. 
• Brief relevant past history M medical problems, medications. 
Specific physical findings: 
• Vital Signs (note respiratory pattern and rate). 
• Level of consciousness (GCS). When assessing children less than 
14 years of age use AVPU. 
• Neurological examination, including pupils and response to 
stimuli, and record findings. NOTE differences between sides. 
(Skill 1 03) 
• External evidence of trauma (abrasions, lacerations, etc.). 
74 
Management: 
Danger, Response, Airway, Breathing, Circulation Disability £xposure. 
Jaw thrust or oropharyngeal airway as needed. Noisy breathing is obstructed 
breathing. 
Be alert for airvJay problems and/or seizure activity. If indicated, consider advanced 
airway management. 
Oxygen, high concentration or 100% (venti13le if necessary) to maintain oxygen 
saturation of at iaast 90%. 
lmmobilise cervical spine with collar and sandbags. Patients with suspected 
head/neck in~ury may be agitated and may not to!erate application of collars. Do not 
force collar~ on under these circumstances. 
Scalp bleeding may be stopped by direct local pressure. If the underlying skull is 
unstable, pressure should be applied to the periphery of the laceration over intact 
bone, using a lar~e pad. I 
If patient has other senou::; lnjuries, these will have priority. I 
If evidence of poor peripheral perfusion, administer i/v fluid to maintain cerebral !I 
perfusion and conscious level Try to maintain a systolic blood pressure of at least 90 
mmHg. Consider MAST if no other option is available. ] 
For longer transport times, if practical manage patient with upper body raised 30° to 
decrease cerebral oedema (unless hypotensive). Ensure head neck alignment is 
maintained. 
If altered mental state, check BSL. 
Monitor Vital Signs and level of consciousness at scene and during transport. 
STATUS CHANGES ARE IMPORTANT. Record findings. 
Specific precautions/notes: 
• The most important information you provide for the hospital is 
TIME SEQUENCE OF LEVEL OF CONSCIOUSNESS. 
• Is the patient stable, deteriorating or improving? 
• Assume cervical spine injury in all patients with significant head 
trauma. 
• Any patient with even a transitory loss of consciousness should be 
assumed to have sustained significant trauma to the brain. 
IF PATIENT WITH HEAD TRAUMA IS IN SHOCK, LOOK ELSEWHERE FOR 






Restlessness/aggressiveness can be a s1gn of hypoxia Corobral hypoxia is 
tho most frequent cause of death in head injury. /1. c;ooD AIRWAY IS 
ABSOLUT[LYVIIAL 
The llf:<-Hl lflJlHt'd pt~tu~nl wtth ,-i c.omprCHllt~,l~d ;ww<ty .;twl:H ~){~ flliln<l(Jf:d tn the 
lateral pnslti(Jn whrlr: t'llSLJflfl(J sr1n,ll prt.>Cilu!HH1S cmd provtrll!l~l ht~Jh 
concentrilttnt; 0. dnr! v(~nt!latnly support 1f ft'IJlmt:d 
It shm1ld tH-' ;HI .;fkt~r:, I,._ASJ RESORT to ddmaw:;ter d secJ;-lllllD <~qent to i1 
h~<td lllJ!I!'~'I p;~t 1·n! S1:dd!1n~~ dgr;nt~; such as ben.to(ltcll.epHil:S GHl precipitate 
lcuge !alb 111 LJiqr ;d pr1 ·:,~:;we ;md cli:pH::.s re:.p11 ;lttOI'rS ·T tw:;t~ factors contr tbute 
to p001 p;i!a·r·,t r--;LJ!I rmw SI:Jrnflf~dll!ly lllOf'aSIIl'j rnor!,llt!y SeJ,ltmn may bt: 
used 111 '->ltull riP~t''-. .,.,lu·rl ttl\:rt· ,., no other option I\J f<!CIIi!(lte <-;;1ft: and r<-1p1d 
transport 
An officer shoulrl NEVER_<lltt~mpl to sed<1lt~ for t11e purpose uf 1ntubnt1ng head 
lnJLHed pi:l!lerrts 1 h1~; rt:qLwes larsw dost:s of sed<~tron and tncreases rtsk of 
deatll t)y thrt'e tr; !CJLH llflll'~; 
Copyr1ght StJohn Arnbulance W A 
Citn1cal Pract1Ce GUidelmes September 20 
Allfll'lltli.\ .'. 











SysloltC Biood Pressure 
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Appt'ndh 4. 


















Bo~ plot dl•mnm•trall•,.; normnlit~· for R~.·spiratiun Rate in mitlnlnhuu/nun 
mitl:11.nl:un cuhnrt 
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Resp~raliOn Rate rests per m•n 
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Systol1c Blood Pressure 
Allpendh; H. 








Systol1c Blood Pressure 
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Appl'ntlix 9. 















Appendix I II. 



























Respnalion Rate rests per m1n 
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Appt.•mlix 12. 

















Resp1ra\10n Rate res1s per m1n 
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Appl•ndix U. 













Pulse Rate beats per mm 
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Pulse Rale beals per mm 
Appendix 15. 
Hox plot demonstrates norm:11ity fur Syslulic Blood l,rcssurc in age catc~OI'}' less 














Box plot demonstrates normality for Systolic Blood Pressure for age category 




age> 35 ears 
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0 
Systolic Blood Pressure 
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Appendix 17. 
Box plot demonstrates normality for Oxygen Saturation for age category less than 
35 years 











Box plot demonstrates normality for Oxygen Saturation for age category greater 
than 35 yc11rs 

















Box plot demonstrates normality for Respiration Rate for age category less than 35 
years 














Box plot demonstrates normality for Respiration Rate for age category greater 













Respiration Rate rests per min 
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Appendix 21. 
Box plot demonstrates normality for Pulse Rate for age category less than 35 years 





Pulse Ra1e beats per min 
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Appendix 22. 






age> 35 ears 
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0 
Pulse Rate beats per min 
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Appendix 23. 













Systoic Blood Pressure 
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Appendix 24. 















Systolic Blood Pres~.oure 
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Appendix 25. 










































Respiration Rate rests per min 
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Appendix 28. 
Box plot demonstrates normality for Respiration Rate in moderate/severe TBl 
cases 











Respiration Rate rests per min 
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Appendix 29. 














Pulse Rate beats per min 
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Appendix 30. 
Box plot demonstrates normality for Pulse Rate in moderate/severe TBI cases 
moderate I severe TBI 
- r 
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Pulse Rate beats per min 
104 
